Introduction {#s1}
============

Reproduction is an energetically costly process triggering multiple physiological adaptations of organs such as liver, pancreas and gastrointestinal tract upon pregnancy in various species ([@bib29]; [@bib74]). As a part of the hormonal response to mating and increased metabolic energy consumption, the female *Drosophila melanogaster* midgut is remodeled in size and physiology by stimulating intestinal stem cell (ISC) driven epithelial expansion to achieve an even energy balance ([@bib19]; [@bib45]; [@bib71]).

Since the discovery of adult intestinal stem cells ([@bib57]; [@bib62]), local signaling pathways such as Notch (N), Jak/Stat, EGFR, Wnt/wingless, Insulin-receptor, Hippo/Warts and Dpp-signaling were shown to contribute to intestinal homeostasis under physiological and challenged conditions like bacterial infections ([@bib58])(and references therein). The midgut epithelium is maintained by ISC giving rise to only two types of differentiated cells: enteroendocrine cells (EE) and absorptive enterocytes (EC) ([Figure 1A](#fig1){ref-type="fig"}). Pluripotent ISC are able to self-renew or divide asymmetrically into either committed EC precursor cells called enteroblasts (EB) or enteroendocrine precursor (EEP) cells. EEP, upon timely activation of *scute* in ISC, divide once more prior to terminal differentiation yielding a pair of EE ([@bib17]; [@bib57]; [@bib62]; [@bib63]). Nine out of ten ISC mitosis give rise to EB specified by N-activation in EB daughters ([@bib57]; [@bib62]; [@bib63]). Post-mitotic EB retain a certain degree of plasticity by: (1) delaying their terminal differentiation through mesenchymal-to-epithelial transition (MET) ([@bib5]), (2) changing their fate to EE upon loss of the transcription factor *klu* (*klumpfuss*) and (3) undergoing apoptosis as an additional homeostatic mechanism ([@bib48]; [@bib72]).

![The Ecdysone receptor in intestinal progenitors controls tissue homeostasis.\
(**A**) Scheme of the adult *Drosophila melanogaster* gastrointestinal tract with cartoon depicting the midgut epithelial monolayer composed of intestinal stem cells (ISC), enteroblasts (EB), enterocytes (EC) and enteroendocrine cells (EE) colored according to the lineage tracing system ReDDM with esg-Gal4 ([@bib5]). (**B**) Schematic of *esg^ReDDM^* tracing including full genotype. *ReDDM* differentially marks cells having active or inactive *Gal4* expression. Combined with *esg-Gal4,* active in ISC and EB, *esg^ReDDM^* double marks ISC and EB driving the expression of *UAS-CD8::GFP* (membrane CD8::GFP, green), *UAS-H2B::RFP* (nuclear H2B::RFP, red) and further UAS-driven transgenes (UAS abbreviated as \>hereafter in Figure panels). Newly differentiated EC and EE with inactive *esg-Gal4* are RFP^+^-only owing to protein stability of H2B::RFP. Flies are grown at permissive 18°C in which transgene expression is repressed by ubiquitous tubulin-driven Gal80^ts^. By shifting adult females to the restrictive temperature of 29°C, Gal80^ts^ is destabilized, in turn enabling ReDDM-tracing marking progeny (EE and EC with H2B::RFP nuclear stain) and in parallel manipulation by allowing transactivation of UAS-sequences through *esg-driven* Gal4-expression ([@bib5]). Posterior midguts (PMG) after seven days of *esg^ReDDM^* tracing of control (crossed with *w^1118^*) adult MF (**D**) show mating dependent addition of new EC compared to control VF (**C**) ([@bib71]). (**E**) Knockdown of EcR using UAS-driven RNAi abolishes mating induced new EC generation in MF. (F+G) Overexpression of \>*EcR.B2* in VF (**F**) and \>*EcRFlyORF^FlyORF840^* (**G**) does not induce proliferation or differentiation of progenitors (ISC+EB). (**H--I**) Quantification of progenitor numbers (**H**) and traced progeny encompassing EC and EE (**I**) in R5 PMG (n = 24,17,17,17, 8). Error bars are Standard Error of the Mean (SEM) and asterisks denote significances from one-way ANOVA with Bonferroni\'s Multiple Comparison Test (\*p\<0.05, \*\*p\<0.01; \*\*\*p\<0,001; \*\*\*\*p\<0.0001). (**J**) Cartoon depicting experimental manipulations on EcR signaling pathway investigated with *esg^ReDDM^*. Scale bars = 100 µm.\
Figure 1---source data 1.Data from [Figure 1](#fig1){ref-type="fig"}.Panel G,H experimental data.](elife-55795-fig1){#fig1}

Apart from aforementioned local signaling pathways, systemic hormones are released into the hemolymph and act on distant organs ([@bib23]; [@bib51]; [@bib71]). Upon mating, JH released by the neuroendocrine *corpora allata* is able to control ISC proliferation through heterodimers of *Met (methoprene-tolerant)* and *gce (germ cells expressed)* nuclear hormone receptors ([@bib71]). JH coordinates *Drosophila* larval development in concert with the steroid hormone 20-hydroxy-ecdysone (20HE) and both hormones stimulate egg production in adult females ([@bib10]; [@bib25]; [@bib49]; [@bib89]). In mated adult female flies, we confirmed an increase of 20HE titers in ovary and detected a similar increase of hemolymph 20HE titers compared to virgin females ([@bib4]; [@bib26]; [@bib30]). The anatomical proximity of ovaries and the posterior midgut (PMG) prompted us to investigate a role for the Ecdysone-receptor (EcR) signaling cascade in organ plasticity during reproduction. Downstream of EcR activation, we detected upregulation of *Ecdysone-induced protein 75B (Eip75B)* protein isoforms ensuring absorptive EC production upon mating. Using the established Notch tumor paradigm, we found that 20HE through Eip75B/PPARγ remote controls EB differentiation and suppresses N-loss of function driven hyperplasia. The mechanism identified in this study not only plays a role in the physiology of mating, but also contributes to our understanding of the protective effects of steroid hormone signaling in the pathophysiology of human colorectal cancer.

Results {#s2}
=======

*EcR* controls intestinal stem cell proliferation and progenitor differentiation {#s2-1}
--------------------------------------------------------------------------------

The female fly intestine undergoes various physiological post-mating adaptations including a size increase of the absorptive epithelium ([@bib19]; [@bib45]; [@bib71]). Intrigued by post-mating increases of 20HE titers ([@bib4]; [@bib30]), we explored a role for EcR-signaling in mating adaptations of the adult *Drosophila melanogaster* intestine.

*EcR* encodes for three different splice variants: *EcR.A, EcR.B1* and *EcR.B2* ([@bib18]; [@bib86]), which we detected by PCR in intestinal tissue with highest expression for *EcR.B2* ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Using EcR antibodies detecting all splice variants, we found EcR in ISC (positive for the Notch ligand Delta^+^), EB (Notch responsive element, NRE-GFP^+^) and EC (Discs-large-1, Dlg-1^+^, [Figure 1---figure supplement 1B--D'''](#fig1s1){ref-type="fig"} and [Figure 1A](#fig1){ref-type="fig"} for an overview). To investigate a role for the EcR in intestinal tissue homeostasis, we first manipulated EcR function in ISC and EB using the *'ReDDM'* (Repressible Dual Differential Marker, [Figure 1B](#fig1){ref-type="fig"}) tracing method to observe its overall impact on tissue renewal ([@bib5]). Briefly, *ReDDM* differentially marks cells having active or inactive *Gal4* expression with fluorophores of different stability over a defined period of time. Combined with the enhancer trap *esg-Gal4,* active in progenitors (ISC and EB), *esg^ReDDM^* double marks ISC and EB driving the expression of *UAS-CD8::GFP* (*\>CD8::GFP*) with short half-life and *\>H2B::RFP* with long half-life. Upon epithelial replenishment, CD8::GFP signal is lost and new terminally differentiated EC (Dlg-1^+^) and EE (Prospero, Pros^+^) stemming from ISC divisions retain a RFP^+^-nuclear stain due to fluorophore stability ([Figure 1A,B](#fig1){ref-type="fig"}; [@bib5]). Crosses are grown at 18°C in which transgene expression is repressed by ubiquitous tubulin-driven temperature sensitive Gal80^ts^. By shifting adult females to 29°C, Gal80^ts^ is destabilized, in turn enabling spatiotemporal control of *esg^ReDDM^*-tracing and additional UAS-driven transgenes in progenitors ([Figure 1B](#fig1){ref-type="fig"}).

After seven days of *esg^ReDDM^*-tracing, mated females (MF, [Figure 1D](#fig1){ref-type="fig"}) showed increases of progenitor numbers ([Figure 1H](#fig1){ref-type="fig"}) and newly generated progeny (EE+EC, [Figure 1I](#fig1){ref-type="fig"}) in the R5 region of the PMG over virgin females (VF, [Figure 1C](#fig1){ref-type="fig"}) confirming previous observations ([@bib71]). Reducing *EcR*-levels with two different *\>EcR* RNAi stocks in MF resulted in a reduction of ISC/EB numbers ([Figure 1E,H](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1L](#fig1s1){ref-type="fig"}) and newly generated progeny ([Figure 1E,I](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1L](#fig1s1){ref-type="fig"}) to levels comparable to VF controls ([Figure 1C,H,I](#fig1){ref-type="fig"}). We confirmed knockdown efficiency of \>*EcR* RNAi in *esg^ReDDM^* by measuring fluorescence intensity of EcR in progenitor cells in situ and found EcR-protein levels significantly decreased in both RNAi lines ([Figure 1---figure supplement 1E--H](#fig1s1){ref-type="fig"}).

Independent of EcR-abundance, we found that expressing dominant-negative *EcR.B2* isoforms or *EcR*-heterozygosity using *EcR^M554fs^*, a well described loss-of-function (LOF) allele, phenocopy \>*EcR* RNAi ([Figure 1---figure supplement 1I--K](#fig1s1){ref-type="fig"}). Generally, *EcR* LOF leads to a similar phenotype as JH-receptor knockdown in MF ([@bib71]). To investigate whether EcR-levels affect progenitor behavior, we overexpressed wildtype *EcR.B2* and *pan-EcR* using *esg^ReDDM^* in VF. We found neither induction of progenitor numbers nor an increase in new EC ([Figure 1F--I](#fig1){ref-type="fig"}), suggesting that EcR-dependent proliferation and differentiation of progenitors might be limited by 20HE availability ([Figure 1J](#fig1){ref-type="fig"}).

Ecdysone titers are increased upon mating and actively transported into progenitors to adapt intestinal physiology {#s2-2}
------------------------------------------------------------------------------------------------------------------

In close anatomical proximity to the PMG, the ovaries are an established ecdysteroidogenic tissue. Determining 20HE titers 48 hr after mating using enzyme immunoassays, we confirmed previous reports of mating dependent increases of ovarian 20HE titers ([Figure 2A](#fig2){ref-type="fig"}; [@bib4]; [@bib30]) and observed a similar increase in the hemolymph ([Figure 2A](#fig2){ref-type="fig"}). As a study investigating the *ecdysoneless* mutants suggested that the ovary is the only source for 20HE in adult females ([@bib24]), we sought to diminish 20HE titers in adult females. Therefore, we genetically ablated the ovaries using the dominant sterile *ovo^D1^* allele in which egg production is blocked prior to vitellogenesis ([@bib11]; [@bib65]; [@bib71]; [Figure 2D](#fig2){ref-type="fig"}). 20HE titers in the hemolymph of *ovo^D1^* females are reduced around 40--50% compared to wild-type females ([Figure 2B,A](#fig2){ref-type="fig"}). Interestingly, 20HE titers in hemolymph and remnants of the ovaries are still significantly increased upon mating of *ovo^D1^* females ([Figure 2C](#fig2){ref-type="fig"}). Consequently, 20HE titers in sterile *esg^ReDDM^*/*ovo^D1^* MF increase the number of progenitors ([Figure 2E](#fig2){ref-type="fig"}) and progeny ([Figure 2F](#fig2){ref-type="fig"}). This suggests that remaining 20HE levels are sufficient to elicit mating related midgut adaptations.

![Intracellular 20-Hydroxy-ecdysone levels control ecdysone response through the ecdysone importer.\
(**A--C**) Determination of 20HE titers in ovaries and hemolymph of wild-type (**A,B**) and *ovo^D1^* (**B,C**) adult VF and MF 48 hr after mating. (**A,C**) show fold-change increases over VF titer (dotted line at y = 1). (**D**) Cartoon depicting ovarian 20HE release to ISC/EB in the adjacent PMG. Please note that in wild-type females, 20HE is incorporated into developing eggs during vitellogenesis, whereas in *ovo^D1^* vitellogenesis is absent and might lead to higher (proportional) release into the hemolymph. 20HE from the hemolymph is absorbed by ISC/EB in the PMG, where the cartoon illustrates specific genetical and pharmacological manipulations on the EcR-signaling pathway. (**E--I**) Representative images of adult PMG after seven days of *esg^ReDDM^* tracing of *ovo^D1^* VF (**E**), *ovo^D1^* MF (**F**) and control VF (**G**) and MF (**H**). (**I**) Control VF PMG after oral administration of RH5849 (50 µg/ml). (**J**) Quantitative RT-PCR on *EcRE* (Ecdysone responsive elements, \[[@bib78]\]) driving lacZ expression on intestinal cDNA from VF and MF control flies. Values are normalized to VF levels (dotted line at y = 1) and statistically analysed using student´s t-test (\*p\<0.05, \*\*p\<0.01; \*\*\*p\<0,001;). (**K--N**) Up- and downregulation of *EcI* in VF (**K,M**) and MF (**L,N**) using UAS driven transgenes after seven days of tracing with *esg^ReDDM^*. (**O**) Quantitative RT-PCR of *EcI* on intestinal cDNA from VF and MF control flies. Values are normalized to VF levels (dotted line at y = 1) and statistically analysed using student´s t-test (\*p\<0.05, \*\*p\<0.01; \*\*\*p\<0,001;). (**P,Q**) Quantification of progenitor numbers (**P**) and traced progeny encompassing EC and EE (**Q**) in R5 PMG (n = 7,9/3,9,5,13/16,13,8,10,10,19). Error bars are Standard Error of the Mean (SEM) and asterisks denote significances from one-way ANOVA with Bonferroni\'s Multiple Comparison Test (\*p\<0.05, \*\*p\<0.01; \*\*\*p\<0,001; \*\*\*\*p\<0.0001). Scale bars = 100 µm.\
Figure 2---source data 1.Data from [Figure 2](#fig2){ref-type="fig"}.Panel A,B,C,J,O,P,Q experimental data.](elife-55795-fig2){#fig2}

20HE is a polar steroid, which disperses through hemolymph and binds to EcR to activate target gene transcription ([Figure 2D](#fig2){ref-type="fig"}; [@bib10]; [@bib25]). Using an established reporter for the activation of 20HE signaling, we found mating induced increases of EcR activity in PMG and ovaries using qPCR ([Figure 2J](#fig2){ref-type="fig"}). As orally administered 20HE is metabolized and cleared of rapidly, we used the potent non-steroidal EcR agonist RH5849. RH5849 is used as pest control due to its stability, specificity and a 30--60 times higher efficacy compared to 20HE ([@bib75]; [@bib95]). Testing concentrations from 1 to 100 µg/ml in timed egg-layings, we observed expected larval molting defects for concentrations from 50 µg/ml upwards ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Feeding control *esg^ReDDM^* VF 50 µg/ml with RH5849, we traced intestinal progenitors with pharmacologically activated EcR-signaling for seven days. RH5849 strongly induces ISC mitosis, reflected by a tenfold increase in newly generated progeny over mating induction ([Figure 2G--I,Q](#fig2){ref-type="fig"}). Interestingly, RH5849 mediated EcR-activation leads to no accumulation of progenitors ([Figure 2P](#fig2){ref-type="fig"}) as observed in oncogenic manipulations or disruptions of intestinal homeostasis, suggesting a role for EcR in both, proliferation and differentiation ([@bib5]; [@bib16]; [@bib67]; [@bib72]). Given the role of 20HE induced programmed cell death (PCD) in larval metamorphosis and the recently discovered role of EB PCD in adult midgut homeostasis ([@bib38]; [@bib39]; [@bib72]), we addressed PCD by activated caspase-3 staining, but found no increase of PCD by RH5849 (data not shown).

Cellular 20HE uptake was recently shown to depend on *Ecdysone Importer (EcI)* belonging to the evolutionary conserved SLCO superfamily of solute carrier transporters. *EcI* LOF causes phenotypes indistinguishable from 20HE and *EcR* deficiencies in vivo ([@bib64]). To investigate a role of EcI, we confirmed membrane localization of *\>EcI* tagged with HA by immunostaining in progenitors using *esg^ReDDM^* ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). After seven days, forced expression of *\>EcI* using *esg^ReDDM^* in VF lead to no increase in progenitor numbers and new EC, underlining that VF 20HE levels are low ([Figure 2K,P,Q](#fig2){ref-type="fig"}). Further supporting this hypothesis,\>*EcI* in MF lead to an increase of newly generated EC exceeding typical mating induction of MF controls by 4.8 fold ([Figure 2L,P,Q](#fig2){ref-type="fig"}). Blocking 20HE uptake by *EcI-RNAi* in MF abolished ecdysone induced tissue expansion to VF control levels ([Figure 2N,P,Q](#fig2){ref-type="fig"}). In addition, we tested a function of the *EcI* gene in mating induction, but found no change in *EcI* expression upon mating ([Figure 2O](#fig2){ref-type="fig"}). Both, pharmacological and genetic experiments, suggest that 20HE titer and import control EcR-activity upon mating ([Figure 2D](#fig2){ref-type="fig"}).

Upon mating, absorptive EC undergo metabolic adaptations upregulating genes known for lipid uptake ([@bib71]). We found EC immunoreactive for EcR ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}) and investigated a function for EcR in mating related upregulation of lipid uptake by measuring the activity of *sterol regulatory element-binding protein* (*Srebp*) ([@bib71]). Therefore, we used a GFP-reporter (*Srebp \>CD8::GFP*) that is subjected to the same proteolytic processing as Srebp ([@bib7]; [@bib71]). Confirming previous observations, *Srebp*-activity increases 2.2 fold upon mating (mean fluorescence intensity, [Figure 2---figure supplement 1C,D](#fig2s1){ref-type="fig"}; [@bib71]). Using the *Srebp-*reporter to drive *\>EcR* RNAi in MF, we found reduced *Srebp-*activity comparable VF controls ([Figure 2---figure supplement 1E--F,H](#fig2s1){ref-type="fig"}), whereas feeding VF with RH5849 induced *Srebp*-activity 2.4 fold ([Figure 2---figure supplement 1G,H](#fig2s1){ref-type="fig"}). Next, we directly addressed lipid uptake with OilRedO-staining on PMG using the EC driver *Mex^ts^*. In accordance with *Srebp*-activity ([Figure 2---figure supplement 1C,D,G](#fig2s1){ref-type="fig"}), feeding flies with RH5849 ([Figure 2---figure supplement 1K](#fig2s1){ref-type="fig"}) and forced expression of EcI ([Figure 2---figure supplement 1L](#fig2s1){ref-type="fig"}) significantly induced lipid uptake ([Figure 2---figure supplement 1O](#fig2s1){ref-type="fig"}) over controls ([Figure 2---figure supplement 1I,J](#fig2s1){ref-type="fig"}). *Mex^ts^ \> EcI* RNAi and *\>EcR* RNAi did not result in a reduction of lipid uptake below control levels ([Figure 2---figure supplement 1M,N,I](#fig2s1){ref-type="fig"}), confirming previous observations of direct fatty acid incorporation into newly produced eggs ([@bib71]).

These data support the idea that mating related synergistic effects of JH- and 20HE-signaling drive adaptation of intestinal homeostasis and physiology. The JH-signal is transduced by the transcription factor *Krüppel-homolog 1 (Kr-h1)* in adult MF intestines, which prompted us to explore a function for the 'classical' Ecdysone target genes ([@bib40]; [@bib71]).

*Ecdysone-induced protein 75b* protein isoforms Eip75B-A and Eip75B-C control enteroblast differentiation {#s2-3}
---------------------------------------------------------------------------------------------------------

During *Drosophila* development, 20HE pulses lead to direct binding of EcR to regulatory regions of early ecdysone response genes *Ecdysone-induced protein 74A (Eip74EF)* and *Ecdysone-induced protein 75B* (*Eip75B*, [Figure 3A](#fig3){ref-type="fig"}; [@bib8]; [@bib42]; [@bib80]). First, we performed conventional PCR to analyze JH- and Ecdysone target gene expression. Signal for *Kr-h1-A (Kr-h1* in the following), but not *Kr-h1-B*, and for all isoforms of *Eip74EF* and *Eip75B* was found ([Figure 3B](#fig3){ref-type="fig"}). Using quantitative real time PCR (qPCR) analysis, we confirmed an increase of JH-pathway activity upon mating using *Kr-h1* as control ([Figure 3C](#fig3){ref-type="fig"}; [@bib71]). To our surprise, we found *Eip74EF* expression unchanged, in contrast to its prominent role in the control of germline stem cell (GSC) proliferation in oogenesis ([@bib1]). Instead, we found induction of *Eip75B-A* and *-C* isoforms ([Figure 3C](#fig3){ref-type="fig"}). *Eip75B* encodes for three protein isoforms (Eip75B-A, -B and --C) that differ in their N-terminal domain structure ([@bib80]) and Eip75B-B lacks one of the two zinc-finger DNA binding domains rendering it incapable of direct DNA binding ([@bib94]).

![*Ecdysone induced protein 75B* is upregulated upon mating and controls progenitor differentiation.\
(**A**) Cartoon depicting EcR signaling cascade activating early ecdysteroid target genes. (**B**) Expression analysis of Ecdysone- and JH-signaling target genes including protein isoforms on cDNA transcribed from mRNA isolations from whole midgut dissections of MF. (**C**) Quantitative RT-PCR on early ecdysteroid genes on intestinal cDNA from VF and MF control flies. Values are normalized to VF levels (horizontal line = 1) and statistically analyzed using student´s t-test (n = 6; \*p\<0.05, \*\*p\<0.01;). (**D--E**) RNAi-mediated downregulation of *Eip75B* in VF (**D**), MF (**E**) and MF fed with RH5849 (**F**) after seven days of tracing with *esg^ReDDM^*. (**G--K**) Representative images of adult PMG with forced expression of *Eip75B* isoforms *Eip75B-A* (**G**)*, Eip75B-A and EcI-RNAi (**H**), Eip75B-B* (**I**), *Eip75B-C* (**J**), *Eip75B-C* and *EcI-RNAi* (**K**) after seven days of tracing with *esg^ReDDM^*. Inset in (**F**) depicts epithelial integration of newly generated Dlg-1^+^/RFP^+^-EC. (**I--J**) Quantification of progenitor numbers (**I**) and traced progeny encompassing EC and EE (**J**) in R5 PMG (n = 12,13,10,12,11,11,14,8,10,10,10,5,11). Error bars are Standard Error of the Mean (SEM) and asterisks denote significances from one-way ANOVA with Bonferroni\'s Multiple Comparison Test (\*p\<0.05, \*\*p\<0.01; \*\*\*p\<0,001; \*\*\*\*p\<0.0001, identical p-values are marked by \# when compared to MF). Scale bars = 100 µm.\
Figure 3---source data 1.Data from [Figure 3](#fig3){ref-type="fig"}.Panel C,L,M experimental data.](elife-55795-fig3){#fig3}

Intrigued by mating increases of *Eip75B-A /- C* levels, we manipulated Eip75B function using *esg^ReDDM^*. Reducing *Eip75B* levels with RNAi, we found a significant increase in ISC and EB numbers ([Figure 3D,E,L](#fig3){ref-type="fig"}), but not in EC generation compared to VF controls ([Figure 3M](#fig3){ref-type="fig"}). In MF, *Eip75B* knockdown reduced newly generated EC compared to MF controls, pointing to a role of *Eip75B* in EB differentiation downstream of EcR-activation ([Figure 3E,M](#fig3){ref-type="fig"}). Interestingly, feeding flies with RH5849 lacking *Eip75B* in their intestinal progenitors ([Figure 3F](#fig3){ref-type="fig"}) did not result in newly generated progeny ([Figure 3M](#fig3){ref-type="fig"} compare to [Figure 2Q](#fig2){ref-type="fig"}), suggesting a central role for Eip75B in the RH5849 response. Additionally, we investigated homozygous *Eip75B-A* mutants using MARCM clonal analysis with a known LOF allele ([@bib70]). MARCM clones of *Eip75B-A* (*Eip75B^A81^*) are significantly larger compared to controls ([Figure 3---figure supplement 1A--D](#fig3s1){ref-type="fig"}; [@bib52]). *Eip75B^A81^* deficient clones contain few differentiated EC (GFP^+^/Dlg-1^+^, [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}) suggesting disturbed EB to EC differentiation as observed for *esg^ReDDM^ \>Eip75* B-RNAi ([Figure 3E](#fig3){ref-type="fig"}). Together, these LOF experiments hint to a role for mating induced *Eip75B-A /- C* isoforms in EC differentiation of EB downstream of EcR.

Forced expression of Eip75B variants with *esg^ReDDM^* resulted in three prominent phenotypes: (1) *Eip75B-A* and *Eip75B-C* strongly drive differentiation into EC (Dlg-1^+^, [Figure 3G,J,M](#fig3){ref-type="fig"}) depleting the entire progenitor pool ([Figure 3G,J,M](#fig3){ref-type="fig"}). (2) The *Eip75B-B* isoform induces ISC proliferation in VF ([Figure 3I](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}) and raised progenitor numbers suggesting slowed down but not inhibited terminal differentiation ([Figure 3I,L,M](#fig3){ref-type="fig"}). (3) All Eip75B manipulations strongly reduce the number of newly differentiated EE ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). This suggests that EE differentiation upon *Eip75B-RNAi* and forced expression of the *Eip75B-B* isoform is blocked ([Figure 3I,L](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). *Eip75B-A* and *Eip75B-C* are sufficient to instantaneously drive progenitors into EC differentiation ([Figure 3G,H,J,K](#fig3){ref-type="fig"}) even in the absence of 20HE import ([Figure 3H,K](#fig3){ref-type="fig"}). The immediate strong differentiation stimulus prevents further ISC division and as a consequence also reduces new EE ([Figure 3L,M](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). Disrupting intestinal homeostasis alters midgut length ([@bib33]) and in line with this, Eip75B manipulations result in a shorter midgut as EC make up around 90% of the whole midgut epithelium ([Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}). Eip75B affects intestinal homeostasis by either slowing down terminal EB to EC differentiation (*Eip75B-B* and *Eip75B-RNAi*) or depleting the ISC and EB pool (*Eip75B-A* */-- C*, [Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}) preventing sufficient EC production along the gut. When EC production is blocked using *\>N* RNAi, the midgut shrinks around one third over a period of seven days ([@bib17]; [@bib28]; [@bib57]; [@bib62]; [@bib63]; [@bib67]). Thus, all Eip75B manipulations ultimately lead to an insufficient number of new absorptive EC resulting in a shorter midgut.

*Eip75B* is a long term predicted *PPARγ*-homologue (*peroxisome proliferator-activated receptor gamma*) in *Drosophila*. A close functional homology got recently confirmed in pharmacogenetic approaches demonstrating that *Eip75B*-mutant flies are irresponsive to PPARγ activating drugs ([@bib41]; [@bib44]). This homology is of particular interest, as human PPARγ plays a role in i) pregnancy related adaptations of lipid metabolism ([@bib93]) and ii) as target in colorectal cancer (CRC) ([@bib77]). Thus, we tested pharmacological activation of Eip75B/PPARγ with the established agonist Pioglitazone, a drug used in Diabetes mellitus treatment ([@bib27]; [@bib36]). Flies fed with food containing Pioglitazone show a strong increase in the number of progenitor cells ([Figure 4B,E](#fig4){ref-type="fig"}) and newly generated EC ([Figure 4F](#fig4){ref-type="fig"}) compared to controls ([Figure 4A](#fig4){ref-type="fig"}). Strikingly, knockdown of Eip75B led to irresponsiveness to Pioglitazone ([Figure 4C,D,F](#fig4){ref-type="fig"}) suggesting that Pioglitazone activates Eip75B in intestinal progenitors.

![The Eip75B/PPARγ agonist Pioglitazone acts through Eip75B to stimulate progenitor differentiation.\
(**A--D**) Representative images of adult PMG after seven days of *esg^ReDDM^* tracing of control MF (**A,B**) and *\>Eip75* B-RNAi MF (**C,D**) fed with DMSO as control (A,C, 2.5 µl/ml food) and Pioglitazone (B,D; 0,002 mg in DMSO/ml food). (E+F) Quantification of progenitor numbers (**E**) and newly generated EC (**F**) in R5 PMG (n = 7,6,10,11). Error bars are Standard Error of the Mean (SEM) and asterisks denote significances from one-way ANOVA with Bonferroni\'s Multiple Comparison Test (\*p\<0.05, \*\*p\<0.01; \*\*\*p\<0,001; \*\*\*\*p\<0.0001,. Scale bars = 100 µm.\
Figure 4---source data 1.Data from [Figure 4](#fig4){ref-type="fig"}.Panel E,F experimental data.](elife-55795-fig4){#fig4}

Taken together, these findings strongly suggested a role for *Eip75B* in EB differentiation. EB are specified by N-signaling and their lineage is maintained by the transcription factor *klumpfuss* (*klu*). *klu^+^*-EB retain some plasticity to change fate to EE upon reduction of *klu-*levels ([@bib48]; [@bib72]). We used *klu^ReDDM^* to explore the function of *EcR* and *Eip75B* in EB lineage identity ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). No changes in EB fate decisions towards EE differentiation were observed upon knockdown of *EcR* and *Eip75B* ([Figure 3---figure supplement 2A,B--D](#fig3s2){ref-type="fig"}). *Eip75B-A* and *Eip75B-C* expression with *klu^ReDDM^* phenocopied EB to EC differentiation effects observed in *esg^ReDDM^* ([Figure 3---figure supplement 2G,I,J,K](#fig3s2){ref-type="fig"}) without non-autonomously inducing proliferation in wild-type ISC of VF and MF ([Figure 3---figure supplement 2J,K](#fig3s2){ref-type="fig"}). Expressing *Eip75B-B* in *klu^ReDDM^* lead to delayed EB differentiation similar to *esg^ReDDM^* and non-autonomous induction of ISC mitosis ([Figure 3I](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2J,L](#fig3s2){ref-type="fig"}; [@bib67]; [@bib72]). Having identified *Eip75B-A /- C* as mating induced differentiation effector of 20HE signaling, we hypothesized and investigated a synergism of 20HE and JH hormonal signaling pathways controlling epithelial expansion upon mating.

The interplay between JH and 20HE in intestinal progenitors {#s2-4}
-----------------------------------------------------------

Our data suggest that mating induced JH and 20HE signaling affect ISC proliferation and EB differentiation through their effectors *Kr-h1* and *Eip75B-A /- C* ([Figure 5K](#fig5){ref-type="fig"}; [@bib71]). In VF lacking mating induction of both hormones ([Figure 2A--C](#fig2){ref-type="fig"}; [@bib4]; [@bib30]; [@bib71]), forced *\>Kr* h1 expression doubles progenitor numbers reproducing previous results ([Figure 5B,I](#fig5){ref-type="fig"}; [@bib71]). Initially, we aimed to perform a full genetic epistasis analysis for *Eip75B* and *Kr-h1,* but this analysis was hampered as we failed to recombine *Kr-h1-RNAi* with *Eip75B* isoform expressing stocks.

![Crosstalk between JH- and Ecdysone-signaling pathways controlling intestinal progenitor proliferation and differentiation.\
(**A--B**) Images of adult PMG of control VF (**A**) and forced expression of *\> Kr* h1 (**B**) traced for seven days with *esg^ReDDM^*. (**C--H**) Images of adult PMG with forced expression of *\> Kr* h1 with *\> Eip75* B-RNAi in VF and MF (**C,D**) and expression of *Eip75B* isoforms *\> Eip75* B-A (**E**)*,\>Eip75* B-B (**F**),\>*Eip75* B-C (**G**) and double *\> Eip75B-RNAi/\>Kr-h1-RNAi* (**H**) after seven days of tracing with *esg^ReDDM^*. Please note that genotypes of (**C--G**) were accompanied with semi-lethality even at permissive 18°C, suggesting for example background transgene expression or position effects most probably caused by the total number of six transgenes including *esg^ReDDM^*. PMG of *\> Kr* h1 combinations also showed some progenitor lethality indicated by membrane-blebbing and irregularities (arrowheads, (**E--G**) as described in [@bib72]. (**J**) Quantification of progenitor numbers (**I**) and traced progeny encompassing EC and EE (**J**) in R5 PMG (n = 12,5,9,8,7,13,8,8,13). Error bars are Standard Error of the Mean (SEM) and asterisks denote significances from one-way ANOVA with Bonferroni\'s Multiple Comparison Test (\*p\<0.05, \*\*p\<0.01; \*\*\*p\<0,001; \*\*\*\*p\<0.0001, identical p-values are marked by \# when compared to MF). Scale bars = 50 µm (**K**) Cartoon depicting transcriptional effectors of JH- and Ecdysone signaling pathways. The JH receptor is formed by a heterodimer of *Methoprene tolerant (Met)* and *germ cells expressed (gce).* Ligand bound receptor activates the transcription of *krüppel homolog 1 (Kr-h1)* mediating mating effects in the adult intestine ([@bib71]) Forced expression of Eip75B-B affects proliferation and differentiation through an yet unknown stimulus.\
Figure 5---source data 1.Data from [Figure 5](#fig5){ref-type="fig"}.Panel I,J experimental data.](elife-55795-fig5){#fig5}

However, we were able to analyze midguts of MF with forced *Kr-h1*-expression and simultaneous *Eip75B-RNAi* ([Figure 5C,D](#fig5){ref-type="fig"}), which increases progenitor numbers ([Figure 5I](#fig5){ref-type="fig"}) with only few newly generated EC ([Figure 5J](#fig5){ref-type="fig"}). This finding supports the requirement of *Eip75B* in EB differentiation ([Figure 3E](#fig3){ref-type="fig"}) and *Kr-h1* in ISC proliferation ([Figure 5A](#fig5){ref-type="fig"}). Simultaneous double knockdown of \>*Kr-h1-RNAi*/*Eip75B-RNAi* ([Figure 5H](#fig5){ref-type="fig"}) in MF did not show mating induction. Progenitor numbers and differentiated progeny are reduced ([Figure 5I,J](#fig5){ref-type="fig"}) phenocopying single *\>Kr* h1-RNAi ([@bib71]). Surprisingly, we observed a strong increase of progenitor numbers forcing *Kr-h1* and *Eip75B-B* expression ([Figure 5F,I,J](#fig5){ref-type="fig"}). These results indicate an additive role of forced *Eip75B-B* and *Kr-h1-*expression on ISC proliferation, whereas the latter transduces the mating related proliferation response ([Figure 3C](#fig3){ref-type="fig"}). The stimulus inducing *Eip75B-B* expression yet needs to be identified ([Figure 5K](#fig5){ref-type="fig"}).

Most interestingly, *Eip75B-A* and *--C*, despite of raised *Kr-h1*-levels, drive progenitors into EC differentiation largely phenocopying sole *Eip75B-A* and *-C* expression (compare [Figures 3G,J](#fig3){ref-type="fig"} and [5E,G,I,J](#fig5){ref-type="fig"}). Our data on *Eip75B-A* and *-C* corroborate a potent role for Ecdysone-induced EB differentiation. ISC fate decisions in the adult midgut rely on N-signaling ([@bib57]; [@bib62]; [@bib63]). During *Drosophila* follicle cell development N opposes EcR-function ([@bib85]), which prompted us to investigate *Eip75B-A /- C* as effectors of EcR-signaling in the context of N-dependent EB differentiation.

Ecdysone signaling through *Eip75B-A* and *Eip75B-C* controls enteroblast differentiation in a notch deficiency tumor model {#s2-5}
---------------------------------------------------------------------------------------------------------------------------

In the *Drosophila* and mammalian intestinal stem cell niche, N-signaling specifies EE and EC fate ([@bib37]; [@bib57]; [@bib62]; [@bib63]; [@bib91]). In *Drosophila*, mitosis of *N* mutant ISC generates only ISC-like progenitor cells and EE, which results in an intestinal epithelium accumulating a lack of newly produced EC and compensatory proliferation ([Figure 6A,B](#fig6){ref-type="fig"}; [@bib17]; [@bib28]; [@bib57]; [@bib62]; [@bib63]; [@bib67]).

![*Ecdysone induced protein 75B* promotes EB differentiation in a Notch tumor paradigm.\
(**A**) Cartoon depicting cell fate changes upon N-LOF combined with *esg^ReDDM^* coloring ([@bib62]; [@bib63]). (**B**) *\> N* RNAi driven by *esg^ReDDM^* leads to different tumor sizes after seven days of tracing that were classified in four classes according to size. Note, ISC-like/EE clusters up to four cells are not quantified as they occasionally occur in controls too. Progenitors are double labelled (GFP^+^/RFP^+^), where newly generated EE are identified by immunostaining for Prospero (Pros) and H2B::RFP trace from *esg^ReDDM^*. (**C--D**) Co- expression of *Eip75B* isoforms *\> Eip75* B-A (**C**) and* \> Eip75* B-C (**D**) after seven days of tracing with *esg^ReDDM^ \> N* RNAi in MF. Note additional Dlg-1^+^-immunoreactivity in (grey,C+D) demonstrating epithelial integration of newly generated cells as EC (Dlg-1^+^/RFP^+^). (E+E') RNAi-mediated downregulation of *Eip75B* in MF shows confluent N-tumors (**E**) accompanied by increased mitosis (**E'**). (**F**) Quantification of ISC progeny encompassing ISC-like and EE total N-tumor number in R5 PMG (n = 10,10,10). (**G--J**) Feeding of the Eip75B/PPARy agonist Pioglitazone to *esg^ReDDM^ \> N^DN^* flies leads to the generation of newly generated EC ((**H,I**), Dlg-1^+^/RFP^+^) after seven days of tracing compared to DMSO controls (**G,I**). (**I--J**) Quantification of ISC progeny encompassing ISC-like and EE total N-tumor number in R5 PMG (n = 5,5). Error bars are Standard Error of the Mean (SEM) and asterisks denote significances from one-way ANOVA with Bonferroni\'s Multiple Comparison Test (\*p\<0.05, \*\*p\<0.01; \*\*\* p\$\$BOX_TXT_END\$\$. \<0,001; \*\*\*\*p\<0.0001). Scale bars = 25 µm.\
Figure 6---source data 1.Data from [Figure 6](#fig6){ref-type="fig"}.Panel F,I,J experimental data.](elife-55795-fig6){#fig6}

Using N-LOF tumors as an experimental paradigm lacking EC production, we sought to investigate the differentiation inducing properties of Eip75B-A /- C. Reduction of N by RNAi or a dominant-negative N-receptor using *esg^ReDDM^* lead to tumors of different sizes, which we quantified and classified according to their number ([Figure 6B](#fig6){ref-type="fig"}). We predominantly found tumors of 5--10 cells ([Figure 6B](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}), but also few tumors containing more than 100 ISC/EE-like cells with indistinguishable single or multiple ISC origin (*class IV*, [Figure 6B](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}).

Co-expression of *Eip75B-A /- C* with N-LOF strongly reduced total tumor number ([Figure 6C,D,F](#fig6){ref-type="fig"}) and smaller *class I*, *II* and *III* tumors ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}), whereas *Eip75B-RNAi* results in confluent *class IV* tumors all along the PMG ([Figure 6E](#fig6){ref-type="fig"}). Although tumor number is strongly reduced ([Figure 6F](#fig6){ref-type="fig"}), occasional *class IV* tumors (\<1/PMG) are able to escape suppressive Eip75B-A /- C showing no reduction in tumor size ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Additional tumorigenic mechanisms such as Upd- or EGF-ligand upregulation may counteract the tumor suppressive function of 20HE signaling in *class IV* tumors ([@bib67]).

Since Eip75B-A and Eip75B-C re-enable EC differentiation despite the lack of N ([Figure 6C,D](#fig6){ref-type="fig"}; Dlg-1^+^/RFP^+^), we investigated whether the EcR-pathway and pharmacological Eip75B-activation are able to trigger EC fate in a N-LOF context. Activation of Eip75B using Pioglitazone led to more newly generated EC ([Figure 6H,I](#fig6){ref-type="fig"}) compared to controls ([Figure 6G](#fig6){ref-type="fig"}). In addition, we observed a slight, but significant reduction in the number of N-tumors upon feeding Pioglitazone ([Figure 6J](#fig6){ref-type="fig"}).

Given the protective role of steroid hormone signaling in colorectal cancer (CRC), we sought to investigate N tumor numbers upon EcR-signaling activation ([@bib14]; [@bib31]; [@bib53]). We activated EcR-signaling with RH5849 ([Figure 7B](#fig7){ref-type="fig"}) or by raising intracellular levels of 20HE expressing \> *EcI* in *esg^ReDDM^*([Figure 7D](#fig7){ref-type="fig"}). Either manipulation resulted in numerous confluent tumors reflecting the previously observed role of 20HE in proliferation ([Figure 7F](#fig7){ref-type="fig"}). In line with this,\>*EcI* RNAi- and *\>EcR* RNAi significantly reduced tumor burden ([Figure 7C,E,F](#fig7){ref-type="fig"}).

![Ecdysone signaling promotes EC-fate in a Notch tumor paradigm.\
(**A--E''**) Pharmacological and genetic manipulation of Ecdysone signaling. Adult PMG of MF with N-LOF (*\>N* RNAi or *\> N^DN^*) treated with MeOH as control (**A--A''**) or RH5849 (**B--B''**) to activate Ecdysone signaling. Arrowheads highlight newly generated Dlg-1^+^/RFP^+^-EC (B+B'') after seven days of *esg^ReDDM^ \> N^DN^*. (**C--C''**) RNAi-mediated downregulation of *EcI* in *esg^ReDDM^ \> N^DN^*, forced expression of *\>EcI* (**D--D''**) and *\>EcR* RNAi (**E--E''**) in *esg^ReDDM^ \> N* RNAi MF after seven days of tracing. Arrowheads highlight newly generated Dlg-1^+^-EC (D+D''), scale bars = 25 µm. (**F**) Quantification of ISC progeny encompassing ISC-like, EC and EE classified after tumor size in R5 PMG (n = 13,5,7,4,6,9). Error bars are Standard Error of the Mean (SEM) and asterisks denote significances from one-way ANOVA with Bonferroni\'s Multiple Comparison Test (\*p\<0.05, \*\*p\<0.01; \*\*\*p\<0,001; \*\*\*\*p\<0.0001). (**G**) Quantification of newly generated EC (Dlg-1^+^/RFP^+^) in R5 PMG (n = 13,5,7,4,6,9). Error bars are Standard Error of the Mean (SEM) and asterisks denote significances from one-way ANOVA with Bonferroni\'s Multiple Comparison Test (\*p\<0.05, \*\*p\<0.01; \*\*\*p\<0,001; \*\*\*\*p\<0.0001). (**H**) Model of 20HE and JH hormonal pathways influencing physiological and pathological turnover in the intestine. Upon mating, JH from the neuroendocrine CA (*corpora allata*, \[[@bib71]\]) as well as ovarian 20HE (**a**) synergize on progenitor cells in the posterior midgut of adult female flies. The source of 20HE could not be definitely determined in this current study and 20HE might as well stem from the brain (**b**). JH induces ISC proliferation through Kr-h1, whereas 20HE signaling transduced by Eip75B-A /- C/PPARγ, ensures that newly produced EB differentiate into EC. New EC lead to a net increase in absorptive epithelium and thus ensures physiological adaptation of intestinal size to the new metabolic energy requirements of pregnancy. In the adult intestine, early steps of tumor-pathology are recapitulated when EC fate is inhibited by the lack of Notch signaling in progenitors ([@bib67]). Notch mutant ISC divisions only produces ISC-like progenitors and EE. We show in this study that 20HE signaling, through Eip75B-A /- C/PPARγ, is capable to alleviate Notch tumor growth by driving intestinal progenitors into post-mitotic absorptive EC fate.\
Figure 7---source data 1.Data from [Figure 7](#fig7){ref-type="fig"}.Panel F,G experimental data.](elife-55795-fig7){#fig7}

More importantly, ecdysone-pathway activation led to significantly higher numbers of newly generated EC (arrowheads in [Figure 7B,D,G](#fig7){ref-type="fig"}), suggesting an upregulation of *Eip75B-A* and *Eip75B-C* in Notch tumors upon EcR-activation through RH5849 and *\> EcI*. To exclude remaining N activity, we generated MARCM clones mutant for *N* (*N^55e11^*) ([@bib28]). In agreement with our previous observations, activating 20HE signaling in N clones led to a tenfold increase in EC numbers over controls ([Figure 7---figure supplement 1A--C](#fig7s1){ref-type="fig"}) and forced expression of *\> E75* A/-C to instant EC formation ([Figure 7---figure supplement 1D--E](#fig7s1){ref-type="fig"}). Interestingly, in the presence of N, its activity is increased upon RH5849 feeding ([Figure 7---figure supplement 1F](#fig7s1){ref-type="fig"}), which suggests an interplay between Notch and EcR-signaling that might converge on *Eip75B* (this study) and *klu* ([@bib48]; [@bib72]).

Taken together, our data establish 20HE as a systemic signal controlling reproductive adaptations in synergism with JH ([Figure 7H](#fig7){ref-type="fig"}). Focusing on EcR-signaling in ISC and EB, we found the mating induced *Eip75B-A /- C* isoforms acting as differentiation factors in EB. Eip75B-A /- C induces EC fate even in Notch-deficient midgut progenitors, an experimental paradigm used to recapitulate early steps of tumorigenesis. Notch dependent fate decisions in midgut precursor cells are conserved between flies and humans. Thus, our findings suggest a new mechanism how steroid hormone signaling might suppress tumor growth by promoting post-mitotic cell fate in intestinal neoplasms marked by a lack of fate specification.

Discussion {#s3}
==========

Systemic hormones and intestinal remodeling upon mating {#s3-1}
-------------------------------------------------------

Growing offspring involves significant metabolic adaptations to raised energy demands in mothers. *Drosophila melanogaster* uses a classical r-selected reproductive strategy with high number of offspring and minimal parental care ([@bib69]). Upon mating, egg production is increased tenfold supported by metabolic and behavioral adaptations such as food intake and transit, nutrient preference and a net increase of absorptive tissue in the PMG depending on JH release ([@bib12]; [@bib19]; [@bib71]; [@bib73]).

Here, we describe a role for the steroid-hormone ecdysone controlling intestinal tissue remodeling upon mating through EcR-signaling. The unliganded heterodimer of EcR and ultraspiracle (USP) binds its DNA consensus sequences serving as a repressor. Upon ligand binding, the EcR/USP heterodimer turns into an activator inducing the expression of early response genes *Eip74EF, Eip75B* and *broad (br)* ([@bib78]; [@bib90]). Initially, we investigated knockdown of *USP, br* and *Eip74EF* in intestinal progenitors and observed effects on progenitor survival independent of mating status ([Figure 3C](#fig3){ref-type="fig"}, Zipper and Reiff, *unpublished data*).

Our data support the idea that 20HE and JH synergistically concert intestinal adaptations balancing nutrient uptake to the increased energy demands after mating ([Figures 1](#fig1){ref-type="fig"}--[5](#fig5){ref-type="fig"}). We confirmed that mating induces ovarian ecdysteroid biosynthesis stimulating egg production by ovarian GSC ([Figure 2A](#fig2){ref-type="fig"}; [@bib1]; [@bib4]; [@bib3]; [@bib30]; [@bib46]; [@bib60]; [@bib90]). In accordance with an inter-organ signaling role for 20HE, we also detected increased 20HE titers in the hemolymph ([Figure 2A](#fig2){ref-type="fig"}). Surprisingly, we found this mating dependent increase of 20HE titers still present upon partial genetic ablation of the ovaries using *ovo^D1^* ([Figure 2B](#fig2){ref-type="fig"}; [@bib71]). This can be explained by either (i) other source(s) for 20HE in adult females like the brain ([@bib15]; [@bib35]) or (ii) 20HE release from remaining germarial cells in stage 1--4 eggs of *ovo^D1^* VF and MF. Indeed, germarial cells have been shown to express the ecdysteroidogenic *Halloween* genes ([@bib4]; [@bib3]). In addition, *ovo^D1^* MF lack ovarian 20HE uptake during vitellogenesis ([Figure 2D](#fig2){ref-type="fig"}) of later egg stages, which potentially contributes to 20HE titer in the hemolymph of *ovo^D1^* females and intestinal epithelium expansion ([Figure 2D,E,J,K](#fig2){ref-type="fig"}; [@bib22]).

The epithelial expansion upon mating of ovo^D1^ females has been observed before ([@bib71]) and might be comparably high due to the different genetic background of *ovo^D1^* flies compared to *w^1118^* ([Figure 2Q](#fig2){ref-type="fig"}). While this work was in review, genetic ablation of ovarian ecdysteroidogenic enzymes was performed in female flies and resulted in a reduction of mitotic ISC. However, a direct assessment of 20HE titers was not performed and a mating dependent context was not analyzed ([@bib2]). Taken together, current data cannot clearly dissect whether the ovary is the exclusive source of 20HE ([@bib24]). In future experiments, 20HE titers have to be directly addressed to investigate whether other sources like the brain might be involved in 20HE release upon mating and other physiological stimuli ([@bib15]; [@bib35]).

In the adjacent posterior midgut, we describe the impact of 20HE on *Eip75B-A /- C* expression ([Figure 7H](#fig7){ref-type="fig"}) and show that 20HE import triggers EcR-activation: i) in VF with low ovarian 20HE levels, overexpression of wild-type *EcR* and *EcI* are unable to elicit neither ISC proliferation nor differentiation effects ([Figures 1](#fig1){ref-type="fig"}--[2](#fig2){ref-type="fig"}). ii) pharmacological activation through RH5849 and Pioglitazone ([Figures 2](#fig2){ref-type="fig"} and [4](#fig4){ref-type="fig"}) as well as (iii) forced *EcI* expression induce proliferation and EB differentiation in MF mediated by *Eip75B-A /- C* ([Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}). Together with the previous findings on JH upon mating ([@bib71]), our current data suggest a concerted role for JH on proliferation and 20HE on differentiation of midgut progenitors.

The interplay between *Eip75B* and *Kr-h1* controls intestinal size adaptation {#s3-2}
------------------------------------------------------------------------------

Downstream of the EcR, we found differential regulation of *Eip75B* isoforms upon mating. *Eip75B* activates egg production in ovarian GSC ([@bib1]; [@bib46]; [@bib60]; [@bib90]) and its knockdown reduces germarial size and number. In accordance with differentiation defects found in EB in our work, the number of cystoblasts, the immediate daughters of GSC, is reduced as well ([@bib1]; [@bib60]).

In our study, we dissected specific roles for *Eip75B* isoforms. *Eip75B-B* expression is at the lower detection limit ([Figure 3B](#fig3){ref-type="fig"}) and unchanged upon mating ([Figure 3C](#fig3){ref-type="fig"}). Thus, our finding that forced *Eip75B-B* expression raised ISC mitosis in VF ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}) might be due to ectopic expression. *Eip75B-B* mutants are viable and fertile and *Eip75B-B* is interacting with DNA only upon forming heterodimers with *Hormone receptor 3 (Hr3)* temporarily repressing gene expression ([@bib9]; [@bib84]; [@bib94]). Further studies of *Eip75B-B,* especially its expression pattern and transcriptional regulation, are necessary to elucidate in which physiological context, else than mating, *Eip75B-B* controls ISC proliferation.

Mating induction of *Eip75B-A /- C,* but not *Eip75B-B,* underlines their differential transcriptional regulation ([@bib80]). This idea is supported by the finding that larval epidermis from *Manduca sexta* exposed to heightened JH-levels is sensitized to 20HE, which results in a 10-fold increase of *Eip75B-A*, but not of *Eip75B-B* expression ([@bib21]; [@bib99]). An in silico analysis of 4 kb regulatory regions upstream of *Kr-h1* using JASPAR revealed several EcR/USP and Met consensus sequences ([@bib43]), suggesting that both hormonal inputs may also converge on *Kr-h1* driving ISC proliferation ([Figure 5B](#fig5){ref-type="fig"}; [@bib71]). We propose a synergistic interplay between JH- and 20HE-signaling upon mating, in which the JH pathway effector *Kr-h1* increases proliferation in ISC and the EcR effectors *Eip75B-A* /- C drive EB into differentiation. The combined action of *Kr-h1* and *Eip75B-A /- C* ensures mating induced organ size growth ([Figures 5K](#fig5){ref-type="fig"} and [7H](#fig7){ref-type="fig"}). The experimental investigation of *Eip75B* and *Kr-h1* regulatory regions incorporating endocrine signals from at least two different organs and leading to differential activity and function in ISC and EB will be a fascinating topic for future studies.

*Eip75B*/*PPARγ* and progenitor fate commitment in physiology and pathology {#s3-3}
---------------------------------------------------------------------------

A key discovery of our study is that systemic 20HE directs local intestinal progenitor differentiation. Upon EcR activation, we found *Eip75B-A /- C* promoting EB to EC differentiation. When tissue demand arises, EB are thought to physically separate from ISC and become independent of N. Detached EB acquire motility and are able to postpone their terminal epithelial integration after initial specification ([@bib5]; [@bib6]; [@bib54]; [@bib82]). Epithelial integration of progenitors can be initiated experimentally by *nubbin (nub)* mediated downregulation of *esg* and the nub-RB isoform is sufficient to initiate EC formation downstream of Notch signaling ([@bib47]; [@bib87]).

Our data suggest, that the ecdysone pathway acting through *Eip75B-A /- C* provides a similar, remotely inducible signal for terminal EB differentiation. This idea is supported by several lines of evidence: i) EB-specific knockdown of *Eip75B* stalls their differentiation using *klu^ReDDM^* ([Figure 3---figure supplement 2E](#fig3s2){ref-type="fig"}), suggesting *Eip75B* functions after initial N-input. ii) *klu*^+^-EB do not change fate upon *Eip75B* knockdown, suggesting a more mature EB differentiation status that already lost plasticity ([Figure 3---figure supplement 2A--D](#fig3s2){ref-type="fig"}; [@bib48]; [@bib72]). iii) Forced *Eip75B-A /- C* expression in EB leads to their immediate differentiation independent of N-input ([Figure 6C,D](#fig6){ref-type="fig"}, [Figure 7---figure supplement 1D,E](#fig7s1){ref-type="fig"}). In addition, *Eip75B* was found to be highly expressed in EB in a recent study from the Perrimon lab ([@bib34]), raising the question about its transcriptional regulation.

A plethora of studies established *Eip75B* as an early response gene downstream of the Ecdysone pathway ([@bib1]; [@bib46]; [@bib60]; [@bib88]; [@bib90]). Another pathway stimulating *Eip75B* expression in EB might be the N pathway. N activation leads to immediate EC differentiation of progenitors and thus phenocopies *Eip75B-A /- C* expression ([@bib33]; [@bib72]). Indeed, 20HE- and Notch-signaling have been shown to converge on target genes in various tissues and functions ([@bib59]; [@bib85]; [@bib96]) and both pathways acetylate H3K56 modifying multiple regulatory genomic regions including *Eip75B* ([@bib83]). We observed that 20HE-signaling leads to the differentiation of progenitors to EC in a N LOF context ([Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}, [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). This is probably the result from strong genetic and pharmacological stimuli ([Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}) acting through Eip75B. 20HE signaling might facilitate the expression of differentiation factors like *Eip75B* as well as *klu* in the presence of N signaling under normal physiological conditions ([Figure 7---figure supplement 1F](#fig7s1){ref-type="fig"}). Future in-depth analysis of *Eip75B* regulatory regions and the generation of *Eip75B* reporter flies will help to understand the interplay of 20HE and N signaling acting on *Eip75B*.

Confirming a close relationship between fly *Eip75B* and human *PPARγ*, we found midgut progenitors responding to the known PPARγ agonist Pioglitazone. In patients, PPARγ plays a role in i) pregnancy related adaptations of lipid metabolism ([@bib93]) and ii) as target in colorectal cancer (CRC) ([@bib77]). Decreased PPARγ levels are associated with development of insulin resistance and failure of lipolysis in obese pregnant women ([@bib76]; [@bib92]). Mating upregulates PPARγ/Eip75B ([Figure 3](#fig3){ref-type="fig"}) and we also describe increased lipid uptake upon EcR-activation ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) in absorptive EC. Srebp, a gene with known function in fatty acid metabolism, is also activated ([@bib32]; [@bib71]; [@bib79]). Studying this interplay between SREBP, PPARγ and steroid hormone signaling will shed light on to which extent adaptation of intestinal size and lipid metabolism contribute to pathophysiological conditions like diabetes.

In CRC, *PPARγ* loss-of-function mutations are observed in around 8% of patients ([@bib77]). *PPARγ* expression correlates with good prognosis and *PPARγ* is epigenetically silenced during CRC progression ([@bib61]; [@bib66]). In agreement with our in vivo experiments on Eip75B-A /- C in EB differentiation ([Figures 3](#fig3){ref-type="fig"}--[7](#fig7){ref-type="fig"}), in vitro studies identified *PPARγ* promoting differentiation in various colon cancer cell lines ([@bib13]; [@bib81]; [@bib97]; [@bib98]).

In a CRC mouse model, biallelic loss of *PPARγ* leads to a 4-fold increase tumor incidence and reduced survival in female mice over males (*Apc^Min/+^/PPARγ^-/-^)* ([@bib56]), whereas males develop around three times more colon tumors with wild type *PPARγ* ([@bib20]). In line with this, ovariectomized *Apc^Min/+^* mice develop significantly more tumors and have decreased *PPARγ* expression, highlighting a possible link between *PPARγ* and estrogen signaling. Meta-analyses of hormone replacement studies have shown that estrogen confers a lower risk to develop CRC and better survival rates for female CRC patients ([@bib14]; [@bib31]; [@bib53]).

It is tempting to speculate that this mechanism of steroid hormones signaling through EcR/ER (estrogen receptor) to activate *Eip75B/PPARγ* is conserved from flies to humans. Indeed, human estradiol and 20HE activate the EcR with similar affinity and elicit *Eip75B* transcription by binding to *EcRE* (Ecdysone-Responsive Elements). *EcRE* can be converted to functional *ERE* (estrogen responsive elements) by a simple change of nucleotide spacing suggesting high conservation ([@bib55]; [@bib78]).

Taken together, our findings reveal that mating induced steroid hormone release, which signals to adjacent intestinal stem cells, controls their proliferation and, more importantly, differentiation of committed precursor cells through *Eip75B/PPARγ.* Ecdysone control of cell fate ensures the production of absorptive enterocytes during mating related intestinal adaptations and induces enterocyte fate in a *Drosophila* intestinal tumor model marked by loss of enterocyte differentiation. Mechanistically, we propose that *Eip75B/PPARγ* exerts an anti-neoplastic role by promoting progenitor differentiation into postmitotic enterocyte fate, thereby reducing the pool of mitotically active cells. Our findings might be a first step towards understanding the protective, but so far mechanistically unclear tumor suppressive role of steroid hormones in female colorectal cancer patients. Downstream of steroidal signaling, Eip75B/PPARγ promotes postmitotic cell fate when local signaling is deteriorated and thus might reflect a promising target for future studies in colorectal cancer models.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                 Designation                  Source or reference                                                                                                                                                                                                                        Identifiers                                                                                                                                     Additional information
  (species) or resource                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  --------------------------------------------- ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Genetic reagent (*Drosophila melanogaster*)   *esg^ReDDM^*                 [@bib5]\                                                                                                                                                                                                                                                                                                                                                                                   [Figures 1](#fig1){ref-type="fig"}--[7](#fig7){ref-type="fig"}; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}
                                                                             DOI: [10.15252/embj.201591517](https://doi.org/10.15252/embj.201591517)                                                                                                                                                                                                                                                                                                                    
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Genetics and fly husbandry/fly strains {#s4-1}
--------------------------------------

*OregonR* and *w^1118^* flies served as wild-type controls. The following transgenes and mutations were employed: *esg^ReDDM^* ([@bib5])*, klu^ReDDM^* ([@bib72]), *UAS-EcI-Flag-HA* ([@bib64]), *UAS-EcI* ([@bib64]), *UAS-EcI-RNAi* ([@bib64]), *UAS-Eip75B-A-Flag* ([@bib70]), *UAS-Eip75B-B-Flag* ([@bib70])*, UAS-Eip75B-C-Flag* ([@bib70]), *UAS-N^DN^* (J. Treisman)*, Dl::GFP* (F. Schweisguth), *N^55e11^ FRT19A* ([@bib28]), *Srebp-GAL4* ([@bib50]), *Mex-Gal4* ([@bib68]), *Gbe+Su(H)dsRed* (T. Klein). From Bloomington *Drosophila* Stock Center (BDSC): *UAS-EcR-RNAi* (*BL58286*), *UAS-EcR.B2* (*BL4934*), *UAS-EcR.B2^W650A^* (BL9449), *UAS-EcR.B2^F645A^* (BL9450), *EcR^M554fs^* (BL4894)*, EcRE-lacZ (BL4516), Eip75B^A81^*(BL23654), *UAS-CD8::GFP* (*BL5137*), *ovo^D1^* (BL1309), *NRE::GFP* (*BL30727*), *NRE::GFP* (*BL30728*), *Dlg-1::GFP* (BL59417), From Kyoto *Drosophila* Stock Center: *UAS-Kr-h1* (DGRC120052). From FlyORF, Switzerland: *UAS-EcR-HA (F000480)*, *UAS-Kr-h1 (F000495)*. From Vienna *Drosophila* Resource Center (VDRC) *UAS-EcR-RNAi (GD37059), UAS-Eip75B-RNAi (GD44851), UAS-Eip75B-RNAi (KK108399)*, *UAS-N-RNAi (GD14477)*.

MARCM clones {#s4-2}
------------

Mosaic analysis with repressible cell marker (MARCM; [@bib52]) clones were induced in midguts by Flippase under control of a *heat-shock* promoter. Expression of the Flippase was activated for 45 min in a 37°C-water bath to induce positively marked clones. Guts were dissected 5 days after induction. Clones in experimental and control flies were induced in parallel.

Food composition and fly keeping {#s4-3}
--------------------------------

Fly food contained 1424 g corn meal, 900 g malt extract, 800 g sugar beet syrup, 336 g dried yeast, 190 g soy fluor, 100 g agarose, 90 ml propionic acid and 30 g NIPAGIN powder (antimycotic agent) in 20 l H~2~O. Food was cooked for about an hour to reduce bioburden, then filled into small plastic vials and cooled down to RT. Flies were kept at 25°C except for crosses with temperature-sensitive GAL80^ts^ (GAL4 repressor) which were kept at 18°C (permissive temperature) until shifted to 29°C (restrictive temperature) to activate GAL4-mediated transgene expression. Crosses with *esg^ReDDM^* and *klu^ReDDM^* were carried out as described previously ([@bib5]; [@bib71]; [@bib72]). Due to persisting problems with mucous formation on food surface in vials with VF, all experiments distinguishing between mated and virgin female flies were run on food with twice the amount of NIPAGIN. Mucous formation was avoided because of massive induction of tissue renewal by pathogenic stress.

Hormone analogue treatments {#s4-4}
---------------------------

A vial of fly food was reheated in the microwave until it became liquid, the hormone analogues were added, thoroughly mixed and filled into a new vial. For each ml of food 5 µl of RH5849 (340 µM final concentration; 20 µg/µl stock solution, diluted in MeOH; DRE-C16813000, DrEhrenstorfer) was added. As a control, an equivalent volume of carrier solution (MeOH) was added to the food. Hormone analogue treatments were performed for the period of the 7 days *ReDDM* ([@bib5]) shift.

PPARγ agonist treatments {#s4-5}
------------------------

A vial of fly food was reheated in the microwave until it became liquid, the PPARγ agonist was added, thoroughly mixed and filled into a new vial. For each ml of food 2.5 µl Pioglitazone (14 µM final concentration, 2 µg/µl stock solution, diluted in DMSO; Sigma-Aldrich, St. Louis, USA) were added. The equivalent amount of DMSO served as control. Flies were starved in an empty vial for at least six hours to ensure synchronized feeding when set to Pioglitazone. Food was renewed after three days and fly midguts were dissected after five days.

Immunohistochemistry {#s4-6}
--------------------

Guts were dissected in PBS and transferred into 4% PFA immediately after dissection and staining was performed on an orbital shaker. After 45 min of fixation guts were washed once with PBS for 10 min. Antibodies were diluted in 0.5% PBT + 5% normal goat serum. The incubation with primary antibodies (1:250 anti-Dlg-1 \[mouse; Developmental studies Hybridoma Bank (DSHB)\]; 1:50 anti-Pros \[mouse; DSHB\]; 1:2000 anti-pH3 \[rabbit; Merck Millipore, 06--570\]; 1:50 anti-EcR common Ag10.2 \[mouse; DSHB\]; 1:500 anti-HA High Affinity 3F10 \[rat; Merck, Sigma-Aldrich\]; 1:1500 anti-ß-Galactosidase preabsorbed \[rabbit; Cappel Research Products\]) was performed at 4°C over night. After washing with PBS guts were incubated with secondary antibodies (1:500 Goat anti-MouseAlexa647 \[Invitrogen\]; 1:500 Goat anti-RatAlexa647 \[Invitrogen\]; 1:500 Goat anti-RabbitAlexa647 \[Invitrogen\]) and DAPI (1:1000; 100 µg/ml stock solution in 0.18 M Tris pH 7.4; DAPI No. 18860, Serva, Heidelberg) for at least 3 hr at RT. Guts were washed a last time with PBS prior to mounting in Fluoromount-G Mounting Medium (Electron Microscopy Sciences).

X-Gal staining of *Drosophila* midguts {#s4-7}
--------------------------------------

Guts were dissected in PBS and transferred into 4% PFA immediately after dissection. After 20 min of fixation, guts were washed three times with 0.3% PBT. Stainingbuffer (0.15M NaCl; 1 mM MgCl~2~; 10 mM Na-phosphate buffer pH 7.2; 3.3 mM F3Fe(CN)6, 3.3 mM K4Fe(CN)6; 0.3% Triton X-100) was heated to 65°C and 3% X-Gal added. The guts were stained for at least 1 hr at 37°C until a dark blue staining became visible. Guts were washed two times in 0.3% PBT prior to mounting in Fluoromount-G Mounting Medium (Electron Microscopy Sciences). Stained midguts were imaged using an Axiophot2 microscope (Carl Zeiss) equipped with an AxioCam MRc (Carl Zeiss).

OilRedO staining of *Drosophila* midguts {#s4-8}
----------------------------------------

Guts were dissected in PBS and transferred into 4% PFA immediately after dissection. After 45 min of fixation, guts were washed in consecutive applications of 1xPBS, double-distilled H~2~O, and 60% isopropanol. Guts were stained in a 6:4 dilution of OilRedO (Sigma-Aldrich, 0.1% stock solution diluted in isopropanol) in dH~2~O for 20 min, then washed in 60% isopropanol and dH~2~O. After mounting in Fluoromount-G Mounting Medium (Electron Microscopy Sciences, emsdiasum) PMG were imaged using an Axiophot2 microscope (Carl Zeiss) equipped with an AxioCam MRc (Carl Zeiss). OilRedO staining intensity was analyzed using Fiji. RGB channels were split and the green channel was subtracted from the red channel to eliminate background signal. A fixed threshold was set, and guts were manually outlined as a ROI. The mean intensity of the resulting signal within the ROI was measured.

Image acquisition {#s4-9}
-----------------

Posterior midguts were imaged using an LSM 880 Airyscan confocal microscope (Carl Zeiss) using 'Plan-Apochromat 10x/0.45 M27', 'Plan-Apochromat 20x/0.8 M27' and 'C-Apochromat 40x/1.20 W Corr M27' objectives. Image resolution was set to at least 2048 × 2048 pixels. At least three focal planes (1 µm distance) were combined into a Z-stack to image one cell layer and to compensate for gut curvature.

For determining whole midgut length, an Axio Zoom.V16 (Carl Zeiss) was employed with DAPI filter and 1x/0.25-objective.

Quantification of proliferation and intensity measurements {#s4-10}
----------------------------------------------------------

Maximum intensity projections were calculated from Z-stack images of PMG by Fiji (ImageJ 1.51 n, Wayne Rasband, National Institutes of Health, USA). Total cell number and RFP-positive cell count of *ReDDM* ([@bib5]) guts were analyzed semi-automatically by a self-written macro for Fiji whereas GFP-positive cells were counted manually (macro available from the authors).

For fluorescence or OilRedO intensity measurements, intestines were scanned with fixed laser/exposure time settings and measured in Fiji. The region of interest was selected manually, and mean intensity of the area was determined. This way, relative EcR and ß-Galactosidase protein levels were measured in antibody-stainings, relative SREBP activity was analyzed in PMG cells expressing *mCD8::GFP* under the control of *Srebp-GAL4*, and amount of triglycerides was analyzed by OilRedO stainings.

Jaspar {#s4-11}
------

The open-access webtool JASPAR ([@bib43]) was utilized to predict transcription factor binding sites within the 5'-UTR of *EcI*. It was specifically scanned for binding motifs related to Ecdysone and Juvenile Hormone signaling.

RNA isolation and cDNA synthesis {#s4-12}
--------------------------------

The R5 regions or ovaries of at least three female flies were dissected and transferred into a droplet of RNA*later* Solution (Invitrogen by Thermo Fisher Scientific) on ice. The tissue was homogenized in 100 µl peqGOLD TriFast (VWR Life Science) and total RNA was isolated as specified by the manufacturer. The following cDNA synthesis was performed with 250 ng of total RNA and the SuperScript IV Reverse Transcriptase (Invitrogen by Thermo Fisher Scientific) using a 1:1 mixture of oligo-dT primers and random hexamers directly upon RNA isolation. Prior to Real-time qPCR, cDNA samples were diluted 1:2 in dH~2~O.

Verification of gene expression in the adult midgut by PCR {#s4-13}
----------------------------------------------------------

To verify gene expression in the adult *Drosophila* midgut, PCRs were performed with primer pairs specific for *ovo* and the *Svb* isoform, or isoform-specific primer pairs for *EcR* spanning at least one exon-exon boundary. PCRs were performed with Q5 High-Fidelity DNA Polymerase (NEB) for at least 30 cycles. Reaction products were loaded on an agarose gel (1.5%) and separated by electrophoresis to verify lengths of PCR products.

PrimerForward (5'−3')Reverse (5'−3')*EcR.A*GGGGTCTAAGAAACATTTTGAGGCCATTTGCAGCTGCAGCCGACGT*EcR.B1*GCACGTACGAAGCCCGATCGCGTCCGGACTCGTTGCCGCAGAGCC*EcR.B2*GCACGTACGAAGCCCGATCGCGTCTCTTCCCTCTGTTCACGCCC*ovo*CGCAGAGCCAAGATGTACGTGGATAGTGGACCTCCGGCT*Svb^Rep^*ACAGTAAGTTGCGAGCCGGTGTTTTGGGGTGTCCTTTCGTG

Real-time qPCR {#s4-14}
--------------

Expression levels of Ecdysone signaling pathway-associated genes were determined in VF and MF. Eclosed *OregonR* or *EcRE-LacZ* flies were aged for 4d before mating. After 72 hr of mating, RNA was isolated and cDNA synthetized before running qPCRs. After an enzyme activation step (20 s 95°C), 40 cycles of denaturation (2 s 95°C), primer annealing (20 s 58°C) and elongation (20 s 72°C) were run. Primers were designed to anneal at 59°C. Reaction was set up with KAPA SYBR FAST Universal (Roche) in a total volume of 10 µl. All qPCR results were normalized to the house-keeping gene *rp49*.

PrimerForward (5'−3')Reverse (5'−3')*Eip74EF-A*AGAAACTTCGAGGCAATAGGGTTGTGCGGCCTCATCTCAAG*Eip74EF-B*TGGCCATCCCACAACGCGGGCGGAAATGAACCTGTTG*Eip75B-A*CCTGTGCCAGAAGTTCGATGAAAGAATCCATCGGCATCTTCGT*Eip75B-B*CGTCTAGCTCGATTCCTGATCTACGGAAGAATCCCTTGCAACC*Eip75B-C*CTGTGGTTCCGGCGGATTTCGAATTCTATGTTGAGTTCTGGTT*EcI*TGCAGTGCCGCTCTCAACTGTACCTCACAGTAACCGTTGACCGCCTCC*EcR.A*GTGTTCGGTGAAAAACGCAATCCTAGCAACTGAGCTTTTGTAGAC*EcR.B1*TTAACGGTTGTTCGCTCGCAAGTGCGGGAAACAATCAGAGCAT*EcR.B2*GTTAACGGTTGTTCGCTCGCTGCGGGAAACAATCAGAGCATA*Kr-h1(A)*ACAATTTTATGATTCAGCCACAACCGTTAGTGGAGGCGGAACCTG*Kr-h1(B)*AAATCTTGGGCACCCAAACAAGTTGTGGCTGAATCTTTCGC*Lac-Z*ATCAGGATATGTGGCGGATGAGCGAGTACAGCGCGGCTGAAATCATC*rp49*TGGTTTCCGGCAAGCTTCAATGTTGTCGATACCCTTGGGC

20-HE isolation and titer determination {#s4-15}
---------------------------------------

20-HE titers were determined in VF and MF of the same age. Eclosed *OregonR* or heterozygous *ovo^D1^* mutant flies were aged for 3d before mating. After 24 hr or 48 hr at least 20 adult female flies were pierced in the thorax with a needle and put into a 150 µl-PCR tube that was punctured in its very bottom. Hemolymph was harvested by centrifugation (5.000x g 5 min RT) and collected in a 1.5 ml-reaction tube. Total weight of flies was determined before and after centrifugation. Typical yields of hemolymph were around 0.6--1 mg. The isolated hemolymph was mixed with 500 µl MeOH, centrifuged (12.000x g 20 min 4°C) and the supernatant was transferred into a new 1.5 ml-reaction tube. MeOH was evaporated at 30°C in a vacuum centrifuge (Eppendorf concentrator plus) and 20HE was resuspended in 100 µl EIA buffer and stored at −20°C until usage.

Ecdysone levels were determined using the 20-Hydroxyecdysone Enzyme Immunoassay kit according to manufacturer's instructions (\#A05120.96 wells; Bertin Bioreagent). 20HE titer was normalized to hemolymph yield.

Statistical analysis {#s4-16}
--------------------

Figures of quantifications were assembled, and statistics were run in GraphPad Prism 6.01. For single comparisons, data sets were analyzed by two-sided unpaired t-test. For multiple comparisons, data sets were analyzed by one-way ANOVA and Tukey's post-hoc test. Significant differences are displayed as \* for p≤0.05, \*\* for p≤0.01, \*\*\* for p≤0.001 and \*\*\*\* for p≤0.0001.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Decision letter after peer review:**

Thank you for submitting your article \"Ecdysone steroid hormone remote controls intestinal stem cell fate decisions via the PPARγ-homologue E75B in *Drosophila*\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Reviewing Editor and K VijayRaghavan as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Jerome Korzelius (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in *eLife* but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand or to explicitly state that the relevant conclusions require additional supporting data.

Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in *eLife*, either of which would be linked to the original paper.

Summary:

In this manuscript, the authors present evidence on the role of 20-Hydroxy-Ecdysone (20HE), secreted from the ovaries, in controlling proliferation and differentiation of intestinal stem cells into Enterocytes in the adult midgut of *Drosophila* females after mating. In the model presented, the authors propose that, following mating, 20HE secreted from the ovaries induce activation of EcR signaling within ISCs/EBs to drive EB differentiation into Enterocytes. They observed differential responses of 20HE on known target genes and followed the role of these target genes on stem cell proliferation and differentiation. The analysis of different isoforms of the ecdysone-target Eip75B reveals different roles for different isoforms of this PPARγ orthologue, with isoforms -A and -C being involved in regulation of EB-differentiation and the -B isoform inducing ISC mitosis. Additionally, activation of EcR signaling in Enterocytes is necessary for metabolic adaptation (lipid metabolism) in the gut in response to mating. Furthermore, the authors analysed the interplay between the 20HE- and the juvenile hormone-pathways. Interestingly, Ec signaling counteracts Notch driven tumourigenesis in the adult midgut.

Overall, this is an impressive volume of work that reveals a novel role for the ubiquitous ecdysone hormone in both ISC proliferation and progenitor differentiation. This connects well with recent work from the Miguel-Aliaga and Perrimon labs that has explored inter-organ communication from neighbouring tissues such as fat body and ovary to the intestine. It also invites further inquiry into the interplay between mating and the Insulin-dependent growth response upon re-feeding of the midgut (O\'Brien et al., 2011).

Essential revisions:

According to the reviewers, there are two major conclusions that need to be revisited to be fully supported.

1\) There is no evidence on the where the source of 20HE comes from. The authors claim that this is the ovary but there is no experimental proof of that. Suppression of 20HE synthesis in the ovary followed by assessment of ISC proliferation/differentiation and gut metabolic adaptation should address this point. Therefore, the systemic control of Ec signaling in the gut needs to be demonstrated. It represents the heart of the paper and what makes it more interesting/novel. In fact, towards the end of the abstract the authors conclude: \'To our knowledge, this is the first time a systemic hormone is shown to direct local stem cell fate decisions. \' This has not been tested and sources other than the ovaries could be playing a role.

2\) The effect of Ec signaling activation on Notch-/- tumours does not prove a direct connection between the two phenomena. This could be the consequence of parallel action of two pathways with opposite effects. Is Ec signaling impaired in Notch tumours? This is key to connect both phenomena and substantiate a major claim of the paper.

The reviewers agreed that the Notch/Ec interaction is a bit overinterpreted in the manuscript, but some re-writing and combining all Notch results in Figure 5 and Figure 6 would fix this. The authors need to soften their claims and acknowledge the limitations of their experiments. This would also leave more room for some of the interesting data from the supplement regarding EE differentiation of E75A MARCM clones or the SREBP activation in Enterocytes to be included in the main manuscript.

Reviewer \#1:

In this manuscript, the authors present data to show that in addition to juvenile hormone (shown in their previous paper, 2017) a second hormone, 20-Hydroxy-Ecdysone (20HE), controls proliferation and differentiation of intestinal stem cells in *Drosophila* females after mating. They used a system established previously, the ReDDM lineage method, to analyse the role of the 20HE-signalling pathway. They applied various genetic and pharmacological perturbations, such as overexpression and knock-down by RNAi and application of the ecdysone agonist, RH5849. They observed differential responses of 20HO on known target genes and followed the role of these target genes on stem cell proliferation and differentiation. They analysed the interplay between the 20HO- and the juvenile hormone-pathways. Finally, they present data to suggest that 20HO-mediated signalling can overcome the defects in differentiation observed upon inactivation of the Notch signalling pathway.

Major points:

1\) Overall, these are interesting data and add novel insight into the way of tissue adaptation to external cues (here: mating). However, as presented here, the reader is supposed to have already detailed knowledge of the topic. In addition, this reader is often lost in details, with no easily understanding the essence. From this point of view, the manuscript would be better suited for a more specialised journal.

2\) The text frequently uses the term \"progenitor differentiation\", based on the expression cell fate markers. Whether these cells differentiate to adopt their cell-type specific features (e. g. absorptive or endocrine) has not been studied. In addition, it is not clear what the authors mean when they state that \"... results implicate EcR-signaling in..... metabolic adaptation of EC\" (last paragraph of Result section).

3\) The authors demonstrate differential effects of 20HO-induced signaling on target gene expression, even on different splice variants of E75B. But how can a transcription factor (the EcR) affect the splicing of this target gene?

4\) The text is often written sloppily, making it sometimes difficult to follow. One example: it reads: \"After N specification, EB lineage is maintained.....\". They probably mean that EBs have been specified by N signalling. The abbreviation N is not explained.

5\) Figure 5 shows that overexpression of E75B-A/-C reduces the number of tumours induced by the absence of N. In addition, they \"re-enable EC differentiation despite the lack of N\". Again, this conclusion is based on the cell fate marker. It could still be that these cells do not differentiate properly at a later stage, they could even undergo apoptosis.

6\) Figure 4: Quantification of all data shown in D-I would be helpful.

7\) Figure 6H is not really clear.

8\) In the Discussion section, some points were not addressed, e. g.

\- What does it mean that E75B-B mRNA is not upregulated in mated females, but its overexpression induces ISC proliferation?

\- How do the authors explain the shortening of the midgut, both upon E75B RNAi and E75B overexpression? Is the diameter enlarged?

Reviewer \#2:

In this manuscript by Zipper et al., the authors present evidence on the role of Ecdysone (Ec/20HE) signaling regulating ISC proliferation and EB differentiation in the adult *Drosophila* midgut. In their model, the authors propose that, following mating, 20HE secreted from the ovaries induce activation of EcR signaling within ISCs/EBs to drive EB differentiation into Enterocytes. Additionally, activation of EcR signaling in Enterocytes is necessary for metabolic adaptation (lipid metabolism) in the gut in response to mating. Interestingly, Ec signaling counteracts Notch driven tumourigenesis in the adult midgut. The work in this report complements a previous publication from the senior author on the role of systemic juvenile hormone influencing proliferation and metabolic adaptation of the female gut in response to reproductive demands. There are, however, inconsistencies in some of the data and key aspects of the model that need more direct demonstration through experiments.

1\) While the role of EcR signaling activation hormone import in the gut is reasonably demonstrated, there is no evidence on the where the source of 20HE comes from. The authors claim that this is the ovary but there is no experimental proof of that. Suppression of 20HE synthesis in the ovary followed by assessment of ISC proliferation/differentiation and gut metabolic adaptation should address this point.

2\) Related to the point above: ISCs proliferation is inferred as the number of esg \>gfp, rfp+ve cells throughout most of the paper. This should be directly measured by looking at pH3 staining.

3\) Similarly, current data on changes in lipid metabolism (Figure S2C-G) should be complemented with direct assessment of gut lipid content.

4\) Are the metabolic and ISC phenotypes influenced by EcR signaling linked? What happens to ISC proliferation if Ec import to the Enterocytes is blocked?

5\) The use of SREBP-gal4 to manipulate gut Enterocytes (Figure S2---figure supplement 1E, F) is unconventional. Mex-gal4 or MyoIA-gal4, should be used.

6\) Images should be presented for the data in Figure 2H.

7\) The phenotype resulting from overexpression of E75B-A and E75B-C appears much stronger than that form EcI overexpression of the use of the EcR agonist. How do the authors explain that?

8\) Genetic interactions presented in Figure 4 should be quantified (ISC proliferation and differentiation) and controls with individual gene manipulations included.

9\) Can the phenotype of EcI overexpression or EcR activation be modified by knocking down E75B? Reciprocally, can E75B-A or -C overexpression rescue EcI knockdown?

10\) The phenotype of E75B-A MARCM clones is unclear. A time course should be done. The authors claim Enteroendocrine cells are lost. However, I cannot see that in the data presented. This should be quantified. EE cell stainings are overall unclear.

11\) The effect of Ec signaling activation on Notch-/- tumours does not prove a direct connection between the two phenomena. This could be the consequence of parallel action of two pathways with opposite effects. Is Ec signaling impaired in Notch tumours? This is key to connect both phenomena and substantiate a major claim of the paper.

Reviewer \#3:

This work describes the role of ecdysone signaling, especially its downstream target Eip75 in midgut homeostasis in *Drosophila*. As ecdysone spikes after mating, and the intestine was already shown to be receptive to JH-signaling from the ovary in previous work by the last author, the authors start with addressing the role of the ecdysone receptor EcR in ISC/EB proliferation and differentiation. Next, the role of the ecdysone-target Eip75B is explored. Interestingly, the analysis of different isoforms reveals different roles for different isoforms of this PPAR-γ orthologue, with isoforms -A and -C being involved in regulation of EB-differentiation and the -B isoform inducing ISC mitosis. The interaction with JH-signaling is investigated and lastly, the role of EcR and its downstream target Eip75B is assessed in Notch LOF-tumors. Altogether, this is an impressive volume of work that reveals a new role for the ubiquitous ecdysone hormone in both ISC proliferation and progenitor differentiation. This connects well with recent work from the Miguel-Aliaga and Perrimon labs that has explored inter-organ communication from neighbouring tissues such as fat body and ovary to the intestine. It also invites further inquiry into the interplay between mating and the Insulin-dependent growth response upon re-feeding of the midgut (O\'Brien et al., 2011). I would recommend this work for publication after the issues described below would be addressed. Especially in the light of the current Covid19-crisis, I do not think extra experimental work should be necessary.

Major comments:

1\) Central to their thesis is the fact that ecdysone produced in the ovary would signal to ISCs/EBs to exert its effect. However, the authors have not done any genetic experiments to show that flies without ecdysone production in the ovary would not have the mating-induced response ISC-EB increase. Hence, a role of local ecdysone production by either the fat body or gut cannot be ruled out. Related to this, the authors decribe determination of 20HE-titers on wild-type and ovoD1 heterozygotes in their Materials and methods section, but no data can be found in the manuscript. Can the authors comment on that and include the 20HE-titer data?

2\) This relates more to the parallels drawn between the work described here and the parallels with mammalian steroid hormone signaling. Based on their results, I do not think the statement that \"our findings suggest a tumor-suppressive role for steroidal signalling \" is warranted. Loss of EcR suppresses ISC/EB proliferation upon mating and the EcR agonist RH5849 dramatically induces proliferation, which would be more in line with an oncogenic effect of EcR-signaling in the fly. I understand that EcR induces Eip75, a PPARγ orthologue and they provide evidence that this induces differentiation and therefore impairs Notch LOF-driven tumorigenesis, in line with mammalian data. I would suggest altering some of these statements and moving them out of the Abstract and Introduction to the Discussion section, where there is more room to elaborate on these contradictions.

10.7554/eLife.55795.sa2

Author response

> Summary:
>
> In this manuscript, the authors present evidence on the role of 20-Hydroxy-Ecdysone (20HE), secreted from the ovaries, in controlling proliferation and differentiation of intestinal stem cells into Enterocytes in the adult midgut of *Drosophila* females after mating. In the model presented, the authors propose that, following mating, 20HE secreted from the ovaries induce activation of EcR signaling within ISCs/EBs to drive EB differentiation into Enterocytes. They observed differential responses of 20HE on known target genes and followed the role of these target genes on stem cell proliferation and differentiation. The analysis of different isoforms of the ecdysone-target Eip75B reveals different roles for different isoforms of this PPARγ orthologue, with isoforms -A and -C being involved in regulation of EB-differentiation and the -B isoform inducing ISC mitosis. Additionally, activation of EcR signaling in Enterocytes is necessary for metabolic adaptation (lipid metabolism) in the gut in response to mating. Furthermore, the authors analysed the interplay between the 20HE- and the juvenile hormone-pathways. Interestingly, Ec signaling counteracts Notch driven tumourigenesis in the adult midgut.
>
> Overall, this is an impressive volume of work that reveals a novel role for the ubiquitous ecdysone hormone in both ISC proliferation and progenitor differentiation. This connects well with recent work from the Miguel-Aliaga and Perrimon labs that has explored inter-organ communication from neighbouring tissues such as fat body and ovary to the intestine. It also invites further inquiry into the interplay between mating and the Insulin-dependent growth response upon re-feeding of the midgut (O\'Brien et al., 2011).
>
> Essential revisions:
>
> According to the reviewers, there are two major conclusions that need to be revisited to be fully supported.
>
> 1\) There is no evidence on the where the source of 20HE comes from. The authors claim that this is the ovary but there is no experimental proof of that. Suppression of 20HE synthesis in the ovary followed by assessment of ISC proliferation/differentiation and gut metabolic adaptation should address this point. Therefore, the systemic control of Ec signaling in the gut needs to be demonstrated. It represents the heart of the paper and what makes it more interesting/novel. In fact, towards the end of the abstract the authors conclude: \'To our knowledge, this is the first time a systemic hormone is shown to direct local stem cell fate decisions. \' This has not been tested and sources other than the ovaries could be playing a role.

We fully agree that the 20HE source and determining 20HE titers were important experiments to perform. 20HE titer measurements in ovaries and hemolymph of VF vs MF are part of Figure 2A-C now. As reviewer 3 commented, we began measuring 20HE titers in wild-type and *ovo^D1^* female flies. Unfortunately, due to the Covid19 crisis, we waited more than 5 months for a last immunoassay Kit to arrive to finally complete three biological replicas. The kit arrived finally two months after the initial submission. The corresponding new data and text were added to:

Results section: "In close anatomical proximity to the PMG, the ovaries are an established ecdysteroidogenic tissue. Determining 20HE titers 48hours after mating using enzyme immunoassays, we confirmed previous reports of mating dependent increases of ovarian 20HE titers (Figure 2A) (Ameku and Niwa, 2016, Harshman et al., 1999) and observed a similar increase in the hemolymph (Figure 2A). As a study investigating the ecdysoneless mutants suggested that the ovary is the only source for 20HE in adult females (Garen et al., 1977), we sought to diminish 20HE titers in adult females. Therefore, we genetically ablated the ovaries using the dominant sterile ovo^D1^ allele in which egg production is blocked prior to vitellogenesis (Busson et al., 1983, Oliver et al., 1987, Reiff et al., 2015) (Figure 2D). 20HE titers in the hemolymph of ovo^D1^ females are reduced around 40-50% compared to wild-type females (Figure 2B,A). Interestingly, 20HE titers in hemolymph and remnants of the ovaries are still significantly increased upon mating of ovo^D1^ females (Figure 2C). Consequently, 20HE titers in sterile esg^ReDDM^/ovo^D1^ MF increase the number of progenitors (Figure 2E) and progeny (Figure 2F). This suggests that remaining 20HE levels are sufficient to elicit mating related midgut adaptations."

Discussion section: "Our data supports the idea that 20HE and JH synergistically concert intestinal adaptations balancing nutrient uptake to increased energy demands upon mating (Figure 1, Figure 2, Figure 3, Figure 4, Figure 5). We confirmed that mating induces ovarian ecdysteroid biosynthesis stimulating egg production by ovarian GSC (Figure 2A)(Ables and Drummond-Barbosa, 2010, Ameku and Niwa, 2016, Ameku et al., 2017, Harshman et al., 1999, König et al., 2011, Morris and Spradling, 2012, Uyehara and McKay, 2019). In accordance with an interorgan signaling role for 20HE, we detected increased 20HE titers in the hemolymph (Figure 2A). Surprisingly, we found this mating dependent increase of 20HE titers still present upon partial genetic ablation of the ovaries using ovo^D1^ (Figure 2B)(Reiff et al., 2015). This can be explained by either (i) other source(s) for 20HE in adult females like the brain (Chen et al., 2014, Itoh et al., 2011) or (ii) 20HE release from remaining germarial cells in stage 1-4 eggs of ovo^D1^ VF and MF. Indeed, germarial cells have been shown to express the ecdysteroidogenic Halloween genes (Ameku and Niwa, 2016, Ameku et al., 2017). In addition, ovo^D1^ MF lack ovarian 20HE uptake during vitellogenesis (Figure 2D) of later egg stages, which potentially contributes to 20HE titer in the hemolymph of ovo^D1^ females and intestinal epithelium expansion (Figure 2D,E,J,K) (Enya et al., 2014).

The epithelial expansion upon mating of ovo^D1^ females has been observed before (Reiff et al., 2015) and might be comparably high due to the different genetic background of ovo^D1^ flies compared to *w1118* (Figure 2Q). Taken together, our current experiments cannot clearly dissect whether the ovary is the exclusive source of 20HE (Garen et al., 1977). In future experiments, complete ablation of ovarian 20HE by genetically removing GSC (Flatt et al., 2008, Kai and Spradling, 2003) or from other sources like the brain need to be performed to address the exact source(s) (Chen et al., 2014, Itoh et al., 2011)."

We also considered that *ovo^D1^* might act directly on intestinal homeostasis due to the induction of EC production (Figure 2Q). A current preprint from Francois Payre and Dani Osman suggests that the EcR induced post translational modification of somatically expressed *shavenbaby (svb^Rep^)* from the *ovo* gene locus controls ISC self-renewal and EC differentiation (Al Hayek et al., 2019). (Consistent with our study, they also observe less progenitors expressing EcR-RNAi and a dominant-negative EcR construct). After consulting the senior authors, a role for *ovo^D1^* acting on somatic *shavenbaby* can be excluded (Francois Payre, University of Toulouse, personal communication) (Andrews et al., 1998, Delon et al., 2003, Mevel-Ninio et al., 1996).

Taken together, we cannot clearly dissect with these experiments whether the ovary (or the remaining cells after *ovo^D1^* ablation) are the exclusive source of 20HE. We now reworked the manuscript accordingly and discuss other sources than the ovaries.

> 2\) The effect of Ec signaling activation on Notch-/- tumours does not prove a direct connection between the two phenomena. This could be the consequence of parallel action of two pathways with opposite effects. Is Ec signaling impaired in Notch tumours? This is key to connect both phenomena and substantiate a major claim of the paper.

The reviewers raise an important and interesting issue. Downstream of the 20HE signaling, we found differential regulation of *Eip75B* isoforms and to investigate their timely expression and function is of high importance, therefore we aimed to tackle them experimentally.

As we discuss in the revised manuscript now, Eip75B might not only be a 'classical' effector of 20HE signaling but also a target of Notch activation. Convergence of EcR and Notch signaling are known from various tissues and functions. Acting together, EcR and Notch were shown to regulate processes like proliferation, differentiation and endocycling/gene amplification by converging on transcription factors like *cut*, *tramtrack* and the broad complex (Mitchell et al., 2013, Sun et al., 2008, Xu et al., 2018).

A possibility how both pathways may converge on *Eip75B* is indicated by a study from Sarah Brays lab. The study suggests that active EcR and Notch, via H3K56 histone acetylation, modify multiple regulatory regions including *Eip75B* (Skalska et al., 2015). A thorough investigation of *Eip75B* regulatory regions is required to elucidate in detail how both pathways may affect *Eip75B*.

Experimentally, we tried to tackle 20HE signaling inside of Notch tumors during the revision process. We followed several approaches:

We investigated EcR activity in Notch tumors by crossing *esg^ReDDM^* flies with *EcRE-LacZ* and *\>N-RNAi*. After X-Gal stainings failed on EcRE-LacZ PMG (reviewer\#2, point6), we performed (i) immunohistochemistry, (ii) qPCR and iii) activating EcR in Notch activity reporter flies:

i\) We used antibodies against the *EcRE-LacZ* gene product β-Galactosidase and compared intra- and extra tumoral EcRE signal intensity (A-D). We found a decrease of β-Galactosidase signal intensity in Notch tumors compared to control ISC/EB (-23,2%, D) and surrounding EC (-22,7%, D). Interestingly this reduction in EcRE-LacZ intensity was restricted to the ISC fraction (B) and no difference was observed in the EE fraction of N-tumors (C).

However, there is conflicting data about the intracellular localization of the EcRE-lacZ gene product in the literature (Kozlova and Thummel 2003, Neto et al., 2017, Okamoto et al., 2018, Schwedes et al., 2011). Okamoto et al., clearly show an enrichment of signal in the nucleus, whereas the original paper from Kozlova, the Schwedes and Neto publications and our images suggest cytoplasmatic localization of the β-Gal enzyme (A-C). Given this discrepancy in the literature, we decided not to include this finding in the main manuscript and state that 20HE signaling is affected in N-tumors. However, we are open to the reviewer's expertise and opinion about including it or not.

ii\) We addressed EcRE-LacZ activity with qPCR in guts carrying Notch tumors (*esg^ReDDM^/\>N-RNAi*, E), but found no significant change compared to control guts (*esg^ReDDM^/+*, E). However this experiment is difficult in its interpretation, as whole gut cDNA is used and changes in the most abundant non-manipulated cells (EC) might occur when N-tumors are induced (Patel et al. 2015). Similar intricacies are true for qPCR for *Eip75B* isoform expression levels in (F), in which we also did not detect any difference in N-tumor (*esg^ReDDM^/\>N-RNAi*) vs. control guts (*esg^ReDDM^/+*) after seven days of tumor induction. FACS sorting of esg^+^-cells for those experiments would sufficiently enrich the ISC/EB fraction to perform these experiments in a more convincing way, but is not readily established.

iii\) In a third experiment, we activated EcR-signaling in Gbe-SuH reporter flies (reviewer 2, point 10) using RH5849 and detected a significant increase in N-activity (G). This experiment shows that under physiological conditions, N activity is indeed impacted by EcR-signaling leading to EC generation (Figure 2I, Figure 7---figure supplement 1F). Thus, our data suggests that *Eip75B* elicits EC differentiation downstream of EcR- and Notch activation, and thus may incorporate signals from both pathways (Figure 3, Figure 4, Figure 6, Figure 7, Figure 3---figure supplement 1, Figure 3---figure supplement 2 Figure 7---figure supplement 1 and reviewer 2, point 10). This interesting interplay on *Eip75B* and also the role of the Notch target gene *klu* warrant future studies (Korzelius et al., 2019, Reiff et al., 2019).

Again, we thank the reviewer(s) for this important comment and adjusted our claims and acknowledged the limitations of our N LOF experiments in the revised manuscript. We added Figure 6---figure supplement 1F to the revised manuscript and now dedicate a paragraph addressing the possible regulation of *Eip75B* by both pathways in the Discussion.
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> The reviewers agreed that the Notch/Ec interaction is a bit overinterpreted in the manuscript, but some re-writing and combining all Notch results in Figure 5 and Figure 6 would fix this. The authors need to soften their claims and acknowledge the limitations of their experiments. This would also leave more room for some of the interesting data from the supplement regarding EE differentiation of E75A MARCM clones or the SREBP activation in Enterocytes to be included in the main manuscript.

We agree and adjusted the claims of our data concerning Notch and 20HE. We re-wrote various paragraphs in the revised manuscript. For details, please see the individual reviews.

> Reviewer \#1:
>
> In this manuscript, the authors present data to show that in addition to juvenile hormone (shown in their previous paper, 2017) a second hormone, 20-Hydroxy-Ecdysone (20HE), controls proliferation and differentiation of intestinal stem cells in *Drosophila* females after mating. They used a system established previously, the ReDDM lineage method, to analyse the role of the 20HE-signalling pathway. They applied various genetic and pharmacological perturbations, such as overexpression and knock-down by RNAi and application of the ecdysone agonist, RH5849. They observed differential responses of 20HO on known target genes and followed the role of these target genes on stem cell proliferation and differentiation. They analysed the interplay between the 20HO- and the juvenile hormone-pathways. Finally, they present data to suggest that 20HO-mediated signalling can overcome the defects in differentiation observed upon inactivation of the Notch signalling pathway.
>
> Major points:
>
> 1\) Overall, these are interesting data and add novel insight into the way of tissue adaptation to external cues (here: mating). However, as presented here, the reader is supposed to have already detailed knowledge of the topic. In addition, this reader is often lost in details, with no easily understanding the essence. From this point of view, the manuscript would be better suited for a more specialised journal.

We thank the reviewer for pointing this out and we have revised our manuscript addressing the reviewer´s concerns. The revised manuscript now aims to underline the more general implications of our findings for the broad readership of *eLife*. As an example, we now include data showing that the PPARγ agonist Pioglitazone acts through Eip75B (Figure 4) that points to a more general relevance of our findings. Regarding the interest for *eLife* readers: We think that for stem cell biologists the demonstration how a hormone acts through Eip75B on progenitor fate decisions is of considerable interest. The *Drosophila* research community profits from the understanding of synergistic action of hormones acting sequentially on different cell types in the context of mating. Finally, for clinical researchers the defined in vivo role of *Eip75B/PPARγ* in intestinal progenitors might be of interest in the future as a plethora of activating and inhibiting ligands is readily available. Our data highlights intestinal progenitor differentiation as a new and important aspect of how hormones are involved in physiological and pathological intestinal homeostasis.

> 2\) The text frequently uses the term \"progenitor differentiation\", based on the expression cell fate markers. Whether these cells differentiate to adopt their cell-type specific features (e. g. absorptive or endocrine) has not been studied. In addition, it is not clear what the authors mean when they state that \"... results implicate EcR-signaling in..... metabolic adaptation of EC\" (last paragraph of Result section).

The ReDDM method combined with esg-Gal4 allows to distinguish between the ISC/EB progenitor cell types (GFP+/RFP+) and the differentiated progeny (GFP-/RFP+, EE and EC, Antonello et al., 2015). Our term RFP-only progeny from the quantifications encompasses terminally differentiated absorptive EC marked by Discs-large-1 (Dlg-1 marks smooth septate junctions in highly polarized cells integrated into the epithelium (Chen et al., 2018a, Furuse and Izumi, 2017, Izumi et al., 2019, Izumi et al., 2016, Izumi et al., 2012)) and EE marked by prospero (Ohlstein and Spradling, 2006). We and other labs did not observe any other differentiated or non-differentiated RFP^+^-only cell type stemming from *esg^ReDDM^* tracings (Al Hayek et al., 2019, Arthurton et al., 2019, Martin et al., 2018, Mundorf et al., 2019, von Frieling et al., 2020).

We now include new supplementing quantification for data in Figure 3 showing that the abundance of EE fate in Eip75B manipulations is less than one new EE (Figure 3---figure supplement 1E) of more than 300 RFP+-only counts (Figure 3M). In various other figures (Figure 5, Figure 6, Figure 7, Figure 3---figure supplement 2 and Figure 7---figure supplement 1), we present images co-stained with terminal differentiation markers Dlg-1 and Pros. For figures in which cell fate changes were investigated, we also now provide quantifications of Dlg-1+/RFP+ upon activated Eip75B (Figure 4F) and 20HE signaling (Figure 6I, Figure 7---figure supplement 1C, Figure 7G) and the induction of EC fate.

Concerning the metabolic adaptation of EC (Figure 2---figure supplement 1C-O), we were referring to the upregulation of Srebp upon mating, which is accompanied by the upregulation of transcripts of fatty acid synthesis (long-chain fatty acid CoA ligases bubblegum (bgm), AcylCoA synthetase long-chain (Acsl), Fatty acid synthase (FAS) and Acetyl-CoA carboxylase (ACC)) described in (Reiff et al. 2015). We additionally provide data now showing RH5849 and *\>EcI* raising lipid uptake by directly addressing lipid uptake with OilRedO stainings (Figure 2---figure supplement 1I-O). We added and rephrased the revised manuscript accordingly.

> 3\) The authors demonstrate differential effects of 20HO-induced signaling on target gene expression, even on different splice variants of E75B. But how can a transcription factor (the EcR) affect the splicing of this target gene?

The reviewer is right and we replaced the term 'splice variant' with protein 'isoform' throughout the manuscript as there is no evidence for alternative splicing of Eip75B. However, it cannot be excluded that such regulation exists for Eip75B gene products as it was recently shown that e.g. JH primes the ecdysteroid response through alternative splicing of *taiman* in mosquitoes (Liu et al., 2018).

> 4\) The text is often written sloppily, making it sometimes difficult to follow. One example: it reads: \"After N specification, EB lineage is maintained.....\". They probably mean that EBs have been specified by N signalling. The abbreviation N is not explained.

We carefully proofread the manuscript again and corrected many phrases that were long and thus difficult to understand. The abbreviation Notch (N) is correctly introduced in the second paragraph of the Introduction. In addition, we prepared a list of abbreviations following the reviewer's suggestion.

> 5\) Figure 5 shows that overexpression of E75B-A/-C reduces the number of tumours induced by the absence of N. In addition, they \"re-enable EC differentiation despite the lack of N\". Again, this conclusion is based on the cell fate marker. It could still be that these cells do not differentiate properly at a later stage, they could even undergo apoptosis.

The cell fate marker (Dlg-1+/RFP+ EC) in new Figure 6 and Figure 7 faithfully reflects terminal differentiation (see reviewer 1, point 2 for references and details).

There are several lines of evidence arguing against a role for PCD in EB survival. (i) We directly addressed programmed cell death with cleaved-caspase 3 feeding flies with RH5849 (mimicking 20HE mating induction) and found no EB death. (ii) PCD in EB is comparably easy to detect by membrane-blebbing and irregularities (GFP+-vesicles) when ReDDM tracing is used (Reiff et al., 2019). (iii) A later PCD as fully differentiated pros^+^-EE and Dlg-1^+^-EC (see reviewer 1, point 2) is unlikely as transgenes are not *esg*- or *klu-Gal4* activated anymore in differentiate cell types (Figures 1A-B, Figure 3---figure supplement 2A). (iv) Upon Eip75B-A/-C expression, ISC/EB progenitor numbers are strongly reduced (Figure 3L). The high number of differentiated cells upon Eip75B-A/-C expression (Figure 3M) argues against a significant contribution of EB-death, but rather shows EB to EC differentiation (inset Figure 3G,H,K) as the main cause of progenitor compartment reduction. Taken together our data argues against a major role of cell loss in neither progenitor- nor differentiated progeny populations.

> 6\) Figure 4: Quantification of all data shown in D-I would be helpful.

In the time after the submission and during the revision, we were able to raise the replica numbers of these genotypes and perform a statistical analysis of all genotypes now. We added this information to new Figure 5 now and incorporated it into the revised manuscript.

> 7\) Figure 6H is not really clear.

New Figure 7H is providing a model of our current and published findings about hormonal control of midgut progenitors in physiology and pathology. We extended and specified its description in the figure legend now.

> 8\) In the Discussion section, some points were not addressed, e. g.
>
> \- What does it mean that E75B-B mRNA is not upregulated in mated females, but its overexpression induces ISC proliferation?

The topic of Eip75B-B regulation is indeed interesting. We already discussed *Eip75B-B* function and regulation in subsection "The interplay between *Eip75B* and *Kr-h1* controls intestinal size adaptation". "In our study, we dissected specific roles for Eip75B isoforms. Eip75B-B expression is at the lower detection limit (Figure 3B) and unchanged upon mating (Figure 3C). Thus, our finding that forced Eip75B-B expression raised ISC mitosis in VF (Figure 3---figure supplement 1F) might be due to ectopic expression. Eip75B-B mutants are viable and fertile and Eip75B-B is interacting with DNA only upon forming heterodimers with Hormone receptor 3 (Hr3) temporarily repressing gene expression (Bialecki et al., 2002, Sullivan and Thummel, 2003, White et al., 1997). Further studies of Eip75B-B, especially its expression pattern and transcriptional regulation, are necessary to elucidate in which physiological context, else than mating, Eip75B-B controls ISC proliferation."

One has to keep in mind that Eip75B-B expression in ISC with UAS constructs is forced and could be ectopic. *Eip75B-B* levels on whole midgut cDNA are low (Figure 3B) and could originate from another cell type than progenitors. The lack of a Zn-finger domain in Eip75B-B and the interaction with Hr3 definitely warrants an in-depth future investigation. We reworked the manuscript concerning this point and highlight now that the stimulus leading to Eip75B-B is unknown (Figure 5K).

> \- How do the authors explain the shortening of the midgut, both upon E75B RNAi and E75B overexpression? Is the diameter enlarged?

We reworked this part of the Results section now and added some details. The text goes as follows now: "Disrupting intestinal homeostasis alters midgut length (Hudry et al., 2016) and in line with this, Eip75B manipulations result in a shorter midgut as EC make up around 90% of the whole midgut epithelium (Figure 3---figure supplement 1G). Eip75B affects intestinal homeostasis by either slowing down terminal EB to EC differentiation (Eip75B-B and Eip75B-RNAi) or depleting the ISC and EB pool (Eip75B-A/--C, Figure 3---figure supplement 1G) preventing sufficient EC production along the gut. When EC production is blocked using \>N-RNAi, the midgut shrinks around one third over a period of seven days (Chen et al., 2018b, Guo and Ohlstein, 2015, Micchelli and Perrimon, 2006, Ohlstein and Spradling, 2006, Ohlstein and Spradling, 2007, Patel et al., 2015). Thus, all Eip75B manipulations ultimately lead to an insufficient number of new absorptive EC resulting in a shorter midgut."

We also added measurements of midguts with Notch-tumors combined with *esg^ReDDM^* to illustrate how much total block of EC production reduces midgut length (\~1/3, Figure 3---figure supplement 1G). Concerning midgut diameter measurements: we found the diameter to fluctuate more than midgut length and also depend on different food recipes. We found measuring midgut length resulting in more robust values in concordance with the work of Bruno Hudry and Irene Miguel-Aliaga (Hudry et al., 2016).

> Reviewer \#2:
>
> In this manuscript by Zipper et al., the authors present evidence on the role of Ecdysone (Ec/20HE) signaling regulating ISC proliferation and EB differentiation in the adult *Drosophila* midgut. In their model, the authors propose that, following mating, 20HE secreted from the ovaries induce activation of EcR signaling within ISCs/EBs to drive EB differentiation into Enterocytes. Additionally, activation of EcR signaling in Enterocytes is necessary for metabolic adaptation (lipid metabolism) in the gut in response to mating. Interestingly, Ec signaling counteracts Notch driven tumourigenesis in the adult midgut. The work in this report complements a previous publication from the senior author on the role of systemic juvenile hormone influencing proliferation and metabolic adaptation of the female gut in response to reproductive demands. There are, however, inconsistencies in some of the data and key aspects of the model that need more direct demonstration through experiments.
>
> 1\) While the role of EcR signaling activation hormone import in the gut is reasonably demonstrated, there is no evidence on the where the source of 20HE comes from. The authors claim that this is the ovary but there is no experimental proof of that. Suppression of 20HE synthesis in the ovary followed by assessment of ISC proliferation/differentiation and gut metabolic adaptation should address this point.

We thank the reviewer for this experimental suggestion. Please find new data and discussion in Essential revisions 1.

> 2\) Related to the point above: ISCs proliferation is inferred as the number of esg \>gfp, rfp+ve cells throughout most of the paper. This should be directly measured by looking at pH3 staining.

We agree with the reviewer that momentary ISC proliferation is best addressed with pH3 or comparable markers of proliferation. However, concerning questions related to homeostatic turnover of the intestinal tissue, cell tracing systems like MARCM clones (Lee and Luo, 2001) and later Bruce Edgars esg-FlpOut (Jiang et al., 2009) and our ReDDM method (Antonello et al., 2015), have been proven highly reliable to address stem cell production over time. One also has to keep in mind that additional regulatory mechanisms like nutrition, delayed differentiation and even EB death strongly affect homeostatic processes and thus momentary ISC proliferation as well (Antonello et al., 2015, O\'Brien et al., 2011, Reiff et al., 2019, Reiff et al., 2015).

Additionally, ISC proliferation was shown to strongly depend on the circadian rhythm (Karpowicz et al., 2013), thus a 'snapshot' of ISC proliferation using pH3 after seven days can be even misleading when overall tissue turnover is not addressed. As a consequence, tracing methods like our ReDDM are now used in many laboratories to address intestinal homeostasis (Al Hayek et al., 2019, Arthurton et al., 2019, Martin et al., 2018, Mundorf et al., 2019, von Frieling et al., 2020).

For a key experiment (Eip75B isoforms), we now include pH3 graphs (Figure 3---figure supplement 1F) and adapted the revised manuscript accordingly.

> 3\) Similarly, current data on changes in lipid metabolism (Figure S2C-G) should be complemented with direct assessment of gut lipid content.

We appreciate this comment and include this experiment now (Figure 2---figure supplement 1F). See reviewer 2, point 5 for details.

> 4\) Are the metabolic and ISC phenotypes influenced by EcR signaling linked? What happens to ISC proliferation if Ec import to the Enterocytes is blocked?

We thank the reviewer for this question, which points to a logical follow up experiment to our current study. Indeed, we are currently performing these experiments in the course of another entire project. EGF and Upd ligands from EC have been implicated to induce homeostatic and stress induced signaling pathways ISC proliferation in various contexts (Jiang et al., 2011, Jiang et al., 2009, Liang et al., 2017).

So far, we can say that there is a role for systemic 20HE being translated into a local signal released from EC, as ISC proliferation is reduced upon 20HE importer RNAi (*Mex^ts^\>EcI-RNAi*). This preliminary data suggests an indirect effect of 20HE acting on EC signaling to ISC, in addition to the direct role for 20HE in ISC and EB described in this current paper.

> 5\) The use of SREBP-gal4 to manipulate gut Enterocytes (Figure 2---figure supplement 1E, F) is unconventional. Mex-gal4 or MyoIA-gal4, should be used.

We agree with the reviewer that the use of Srebp-Gal4 is unconventional and include now OilRedO staining of PMG (Figure 2---figure supplement 1I-O). In Reiff et al., 2015 we showed that *Srebp-Gal4\>CD8::GFP* is the more sensitive tool to address the upregulation of lipid uptake and we were able to detect changes between VF and MF or RH5849 fed flies (Figure 2---figure supplement 1C,D,G). We agree that the measurements done in *Srebp\>EcR-RNAi* might harbor some imprecision due to possible fluctuations of the driver.

The newly included OilRedO-stainings, directly addressing lipid content, show that the RH5849 agonist and the overexpression of *\>EcI* significantly increase lipid content. But why is there no significant decrease when *EcR* and *EcI* are knocked down? One explanation is that there is also very low levels of OilRedO staining in PMG of controls (Figure 2---figure supplement 1I,J). Together with the Miguel-Aliaga lab, we have previously described that the uptake of lipids using OilRedO can be only visualized when egg production is blocked from instantly taking up lipids into developing eggs (Reiff et al., 2015). Therefore, we aimed to reduce egg production with *ovo^D1^*, but could not create viable stocks that harbor *ovo^D1^, Mex\>* and *tub-Gal80^ts^* to perform this experiment. For future experiments, a stock directly driving GFP from the Srebp activity construct used to make Srebp-Gal4 could tackle this problem.

Taken together, we now show that in addition to the activation of Srebp, 20HE signaling activation also leads to higher lipid content directly addressed by OilRedO.

> 6\) Images should be presented for the data in Figure 2H.

The data we presented in Figure 2H is raised with qPCR on R5 tissue to detect small differences in EcRE-lacZ mRNA levels. With images, reviewer\#2 is probably referring to the Schwedes publication (Schwedes et al., 2011), in which X-Gal stainings were performed on EcRE-lacz fly stocks in different tissues. We also performed those stainings (for 1hour \@37°C) for the revision and noted big differences in staining intensity among different gut regions (see [Author response image 2A-C](#sa2fig2){ref-type="fig"}, proventriculus). We were unable to detect differences between VF and MF (A'-B'). An intensity-based evaluation of the above images after β-Gal staining was not successful because of the signal stemming from luminal gut content (A'-C'), which is why we chose to rely on our qPCR data.

However, old flies showed strong staining in the posterior midgut suggesting an age dependency (C,C'). However, it is also possible that the known high protein stability of β-galactosidase leads to a strong signal in 20d old flies. Another explanation is that old flies have higher 20HE titers or other factors augment the response to 20HE in older flies.
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> 7\) The phenotype resulting from overexpression of E75B-A and E75B-C appears much stronger than that form EcI overexpression of the use of the EcR agonist. How do the authors explain that?

This is a very difficult question to address and we will discuss this issue based on our current data: First of all, the strong differentiation phenotype of Eip75B-A and Eip75B-C stems from the direct and forced expression in ISC/EB (*esg^ReDDM^*) or EB (*klu^ReDDM^*). Levels of *Eip75B* isoforms are probably several fold higher than under physiological conditions, but were shown to be able to rescue Eip75B LOF phenotypes in the brain (Rabinovich et al. 2016). Driven by strong *tubulin-Gal4*, we measured around 50-fold increases for all splice variants (not shown), which is much stronger than normal mating induction (Figure 3C). Overexpression with weaker drivers like *esg/klu^ReDDM^* are supposedly milder. A possible experiment to address this directly, would involve FACS sorting of *esg/klu^ReDDM^* marked cells and subsequent qPCR for Eip75B isoforms, which is not established in our lab.

Secondly, we assume 20HE ligand availability as the most probable limiting factor for the activation of EcR. In line with this, *\>EcR* overexpression is unable to induce further proliferation and differentiation (Figure 1F,G). In this revised version, we now show that the overall 20HE titer in the hemolymph (Figure 2A) doubles upon mating. In line with this, we observe an about two-fold increase in progeny in *\>EcI* MF (Figure 2K compared to control MF). In addition, when 20HE (and JH) titers are low in VF, EcI overexpression is not sufficient to elicit an increased number of differentiated cells. Together, we assume ligand availability as the limiting factor for EcR activation.

Feeding flies with the RH5849 non-steroidal EcR agonist affects EB to EC differentiation through Eip75B (Figure 2, Figure 6, Figure 7, Figure 7---figure supplement 1, Figure 3F) and RH5849 elicits EC production similarly to EcI MF (Figures 2Q and 7G). Chipseq, DamID and Cut-Run experiments suggest that EcR is found at between 100-1000 binding sites in the genome depending on the investigated tissue/cell line (Gauhar et al., 2009, Shlyueva et al., 2014, Uyehara and McKay, 2019). Distribution of taken up 20HE or RH5849 might additionally weaken EcR activation on a single gene level (like Eip75B) compared to direct UAS driven *Eip75B* expression. Another important trigger for activation strength of Eip75B might be an additional activation of *Eip75B* through the Notch pathway, which would be circumvented with direct \>Eip75B-A/-C expression. The interplay with Notch is discussed now in the revised manuscript and under reviewer 2, point 10 and the Essential revisions.

> 8\) Genetic interactions presented in Figure 4 should be quantified (ISC proliferation and differentiation) and controls with individual gene manipulations included.

Please see reviewer 1, point 6 and the new Figure 5 for a quantification of ISC/EB numbers and progeny numbers.

> 9\) Can the phenotype of EcI overexpression or EcR activation be modified by knocking down E75B? Reciprocally, can E75B-A or -C overexpression rescue EcI knockdown?

We thank the reviewer for this suggestion and performed the experiments. We include the according panels and quantifications in Figure 3(F,H,K,L,M) now and discuss them accordingly in the revised manuscript.

> 10\) The phenotype of E75B-A MARCM clones is unclear. A time course should be done. The authors claim Enteroendocrine cells are lost. However, I cannot see that in the data presented. This should be quantified. EE cell stainings are overall unclear.

We thank the reviewer for this comment and quantified EE (GFP+/Pros+) cells in *Eip75B-A^(A81)^* MARCM clones. Quantification revealed no significant difference in the number of EE compared to FRT2A controls. We noticed however that clonal EE numbers in FRT2A controls are exceptionally low (compared to FRT40A control clones, see attached quantification (A), 7d after clone induction). Additionally, we analyzed the activation of Notch in Eip75B-A clones using *GBE+Suh-dsRed* reporter flies (B-B'', Grainy head Binding Elements and Suppressor of Hairless Notch activity reporter construct from Sarah Brays lab). We detected no significant difference in Notch signal activity that may have indicated a fate change from EC to EE (Micchelli and Perrimon, 2006, Ohlstein and Spradling, 2006, Ohlstein and Spradling, 2007). We removed the statement from the revised text.
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> 11\) The effect of Ec signaling activation on Notch-/- tumours does not prove a direct connection between the two phenomena. This could be the consequence of parallel action of two pathways with opposite effects. Is Ec signaling impaired in Notch tumours? This is key to connect both phenomena and substantiate a major claim of the paper.

We thank the reviewer for pointing out this important issue. Please find new data and discussion in Essential revisions 1.

> Reviewer \#3:
>
> This work describes the role of ecdysone signaling, especially its downstream target Eip75 in midgut homeostasis in *Drosophila.* As ecdysone spikes after mating, and the intestine was already shown to be receptive to JH-signaling from the ovary in previous work by the last author, the authors start with addressing the role of the ecdysone receptor EcR in ISC/EB proliferation and differentiation. Next, the role of the ecdysone-target Eip75B is explored. Interestingly, the analysis of different isoforms reveals different roles for different isoforms of this PPARγ orthologue, with isoforms -A and -C being involved in regulation of EB-differentiation and the -B isoform inducing ISC mitosis. The interaction with JH-signaling is investigated and lastly, the role of EcR and its downstream target Eip75B is assessed in Notch LOF-tumors. Altogether, this is an impressive volume of work that reveals a new role for the ubiquitous ecdysone hormone in both ISC proliferation and progenitor differentiation. This connects well with recent work from the Miguel-Aliaga and Perrimon labs that has explored inter-organ communication from neighbouring tissues such as fat body and ovary to the intestine. It also invites further inquiry into the interplay between mating and the Insulin-dependent growth response upon re-feeding of the midgut (O\'Brien et al., 2011). I would recommend this work for publication after the issues described below would be addressed. Especially in the light of the current Covid19-crisis, I do not think extra experimental work should be necessary.
>
> Major comments:
>
> 1\) Central to their thesis is the fact that ecdysone produced in the ovary would signal to ISCs/EBs to exert its effect. However, the authors have not done any genetic experiments to show that flies without ecdysone production in the ovary would not have the mating-induced response ISC-EB increase. Hence, a role of local ecdysone production by either the fat body or gut cannot be ruled out. Related to this, the authors decribe determination of 20HE-titers on wild-type and ovoD1 heterozygotes in their Materials and methos section, but no data can be found in the manuscript. Can the authors comment on that and include the 20HE-titer data?

We thank reviewer for pointing to this central issue as well and added this data now. Please find new data and discussion in Essential revisions 1.

> 2\) This relates more to the parallels drawn between the work described here and the parallels with mammalian steroid hormone signaling. Based on their results, I do not think the statement that \"our findings suggest a tumor-suppressive role for steroidal signalling \" is warranted. Loss of EcR suppresses ISC/EB proliferation upon mating and the EcR agonist RH5849 dramatically induces proliferation, which would be more in line with an oncogenic effect of EcR-signaling in the fly. I understand that EcR induces Eip75, a PPARγ orthologue and they provide evidence that this induces differentiation and therefore impairs Notch LOF-driven tumorigenesis, in line with mammalian data. I would suggest altering some of these statements and moving them out of the Abstract and Introduction
>
> to the Discussion section, where there is more room to elaborate on these contradictions.

We followed the reviewer(s) suggestion here and moved and softened statements in Abstract, Introduction and the final paragraph of the Results section. Furthermore, we added experiments with an PPARy agonist impairing Notch driven tumorigenesis and extended and focusing the discussion accordingly (new Figure 4).

Concerning a role for steroidal signaling and tumor suppressive or oncogenic roles: the effects of ER signaling in humans are context dependent. The major functions of steroid hormone receptor signaling in normal adult tissues appear to involve differentiation rather than proliferation (Cheng and Balk, 2003). This role is drastically changed in the pathology of cancer and there is a plethora of studies showing the benefits of blocking ER signaling in breast and prostate cancer (Cheng and Balk, 2003), whereas activation seems to be beneficial for female colorectal cancer patients (Chen et al., 1998, Hendifar et al., 2009, Lin et al., 2012).
